World - PCT Patents in Blood Anticlot Technology, Medications
and Medical Devices

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - WORLD PATENTS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED FROM 1980 TO 2009



Title: THREE-LINE APHERESIS SYSTEM AND METHOD

Publication No: WO2009/129132
Pub. Date - Int. Class - Applicant: - 22.10.2009 - A61M 1/36 - HAEMONETICS CORPORATION
A blood processing system (100) for collecting and exchanging blood components includes a venous-access device (110) for drawing blood and returning blood components to a subject. A blood draw line (120) fluidly connects the venous-access device (110) to the blood component separation device (150). An anticoagulant line (130) connected to the anticoagulant source (134), introduces anticoagulant into the drawn whole blood. A return line (140), fluidly connected to the venous-access device (110) and the blood component separation device (150), and returns uncollected blood component to the subject. A draw pump (122), an anticoagulant pump (132), and a return pump (142), respectively control the flows through the draw line (120), anticoagulant...


Title: SYSTEM AND METHOD FOR PLASMA REDUCED PLATELET COLLECTION

Publication No: WO2009/129131
Pub. Date - Int. Class - Applicant: - 22.10.2009 - A61M 1/36 - HAEMONETICS CORPORATION
A method and apparatus for collecting plasma reduced platelets potentially suspended in a synthetic solution from a donor. Whole blood is drawn from the donor and introduced into a separation chamber (12). Platelets are extracted from the separation chamber into a container (20), using, for example, surge (with anticoagulated plasma or a synthetic solution) or push methodologies. The remaining blood components in the separation chamber are returned back to the donor. The steps of drawing whole blood and introducing the whole blood into the separation chamber, extracting platelets from the separation chamber into the container, and returning the remaining components in the chamber back to the donor are repeated. The sequestered platelets in ...


Title: METHOD OF PROVIDING HEMOSTASIS IN ANTI-COAGULATED BLOOD

Publication No: WO2009/126917
Pub. Date - Int. Class - Applicant: - 15.10.2009 - A61K 33/00 - Z-MEDICA CORPORATION
In a method of clotting blood in which the blood exhibits a reduced tendency to clot and may be from a person undergoing an anticoagulant therapy or having type A or B hemophilia or von Willebrand disease, a therapeutically effective amount of a composition comprising clay as the active ingredient is administered to a wound from which the blood emanates. Upon contacting the blood, this clay, which may be kaolin, bentonite, or any type of layered clay, causes the blood to clot. In a method of arresting blood flowing from a wound, a therapeutically effective amount of a composition comprising clay as the active ingredient is administered to the bleeding wound. In this method, the blood has a reduced tendency to clot and may be from a person u...


Title: ANTICOAGULANTS DERIVED FROM NAJA NIGRICOLLIS SNAKE VENOM

Publication No: WO2009/123573
Pub. Date - Int. Class - Applicant: - 08.10.2009 - C07K 14/46 - NATIONAL UNIVERSITY OF SINGAPORE
A polypeptide having anticoagulant activity is disclosed, the polypeptide having the amino acid sequence of SEQ ID NO: 1 and being derived from Naja nigricollis snake venom, or having an amino acid sequence sharing at least 90 percent sequence identity with the amino acid sequence of SEQ DD NO: 1.


Title: KIT FOR COLLECTING BLOOD, PREFERABLY PERIPHERAL BLOOD, FOR THE PRODUCTION OF STEM CELLS

Publication No: WO2009/115522
Pub. Date - Int. Class - Applicant: - 24.09.2009 - B01L 3/00 - SALES ENGINEERING AG
A kit (10) for collecting blood, preferably peripheral blood, for the production of pluripotent stem cells comprises at least a first container (12), able to contain the blood taken, which contains an anticoagulant and the substance MCSF (Macrophage Colony Stimulating Factor).


Title: INFECTION MEDIATED FOAM DISSOLUTION RATE MEASUREMENT

Publication No: WO2009/111485
Pub. Date - Int. Class - Applicant: - 11.09.2009 - C12Q 1/04 - IMIGENE, INC.
The subject invention concerns methods and materials for determining the presence or absence of bacterial or fungal infection in a blood sample. In one embodiment, a method of the invention comprises exposing an anticoagulant treated blood sample to freezing the sample to a solid, followed by thawing of the sample and then agitation of the sample to develop foam and then observing the rate that foam dissolves.


Title: COMPOSITION AND METHOD FOR TREATING AND PREVENTING MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS

Publication No: WO2009/097228
Pub. Date - Int. Class - Applicant: - 06.08.2009 - A61K 31/122 - SELMAN, Yamil, E.
The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes; of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).


Title: AUTOMATED METHOD AND APPARATUS FOR DETECTING ERRONEOUS SAMPLE COLLECTION IN CLINICAL ASSAYS

Publication No: WO2009/086186
Pub. Date - Int. Class - Applicant: - 09.07.2009 - G01N 27/26 - ABBOTT POINT OF CARE INC.
A method for identifying biological samples that are collected using the wrong anticoagulant for subsequent analytical testing. The method also provides for identification of certain analytical test results that are substantially or partly adversely affected.


Title: ANTICOAGULANT-COATED DIPSTICK FOR USE WITH A BLOOD CENTRIFUGE ROTOR

Publication No: WO2009/058259
Pub. Date - Int. Class - Applicant: - 07.05.2009 - B01L 9/00 - IDEXX LABORATORIES, INC.
An anticoagulant-coated dipstick is selectively receivable by the central fill port of a rotor of a blood centrifuge. The dipstick includes an elongated, rod-like member having a first axial end and an opposite second axial end, and a cap affixed to the second axial end. At least a portion of a surface of the rod-like member is coated with an anticoagulant. The elongated rod-like member of the dipstick is dimensioned in length and diameter to be receivable through the central fill port of the rotor to contact a blood sample contained therein. The cap is circular in shape, with a diameter that is greater than that of the rotor fill port to entirely cover and seal the fill port to prevent leakage therethrough of a blood sample contained in th...


Title: NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES

Publication No: WO2009/049370
Pub. Date - Int. Class - Applicant: - 23.04.2009 - C07H 11/00 - PROGEN PHARMACEUTICALS LIMITED
The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.


Title: ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

Publication No: WO2009/042962
Pub. Date - Int. Class - Applicant: - 02.04.2009 - A61P 7/04 - PORTOLA PHARMACEUTICALS, INC.
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.


Title: INORGANIC COAGULATION ACCELERATORS FOR INDIVIDUALS TAKING PLATELET BLOCKERS OR ANTICOAGULANTS

Publication No: WO2009/023688
Pub. Date - Int. Class - Applicant: - 19.02.2009 - A61K 9/00 - HONEYWELL INTERNATIONAL INC,
The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials to the wound of a patient on anticoagulant or platelet blocker therapy. The method comprises contacting such wounds with a substance selected from the group consisting of zeolitic molecular sieves and non-zeolitic molecular sieves, diatomaceous earth, glass powder or fibers, precipitated or fumed silica, kaolin and montmorillonite clays and Ca exchanged permutites.


Title: NEW ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION

Publication No: WO2008/002229
Pub. Date - Int. Class - Applicant: - 31.12.2008 - C07D 213/73 - OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA'
This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery; and for preventing hypercoagulation conditions in consequence of injuries, surgeries, sepsis, various obstetric pathologies, in disaster medicine, resuscitation, and so on.


Title: ANITCOAGULANTS AS ANTIFOULING AGENTS

Publication No: WO2008/156691
Pub. Date - Int. Class - Applicant: - 24.12.2008 - C09D 5/16 - DUKE UNIVERSITY
Methods and compositions are provided for the reduction of fouling of objects present in marine environments. The methods and compositions include anticoagulants, such as, for example, glycosaminoglycans, coumarin- type molecules, metal chelators, plasminogen activators and platelet inhibitors. The methods include reducing marine fouling, comprising incorporating an anticoagulant compound into a marine coating. In addition, the methods include identifying compounds useful for reducing marine fouling, comprising measuring either blood coagulation or barnacle cement polymerization in the presence and absence of the compound, wherein a reduction in the blood coagulation or the barnacle cement polymerization in the presence of the compound iden...


Title: PROCESS FOR THE PREPARATION AND PHARMACEUTICAL FORMULATIONS FOR 4-QUINOLINONES AND QUINOLINES AND USE THEREOF

Publication No: WO2008/144865
Pub. Date - Int. Class - Applicant: - 04.12.2008 - C07D 215/02 - FUNDA!O UNIVERSIDADE FEDERAL DE SĎ CARLOS
The present invention describes novel 4-quinolinones corresponding to formula (I) and quinoline derivatives thereof as formula (II), process of preparation thereof, pharmaceutical formulations comprising said 4-quinolinones and pharmaceutical application thereof for diseases related to disorders of white blood cells, such as inflammatory and autoimmune diseases, including rheumatism, as well as the use as anti-coagulant, antivenin, analgesic and for antithrombotic purposes.


Title: FLUID INJECTION AND SAFETY SYSTEM

Publication No: WO2008/144575
Pub. Date - Int. Class - Applicant: - 27.11.2008 - A61B 5/145 - OPTISCAN BIOMEDICAL CORPORATION
Various medical systems and methods are described, including a medical monitoring system ( 102, 400, 700, 800, 2632). The medical monitoring system can have a fluid system (404, 510. 801, 901) configured to receive bodily fluid and optically analyze said fluid to determine analyte concentration. The fluid system can have a removable portion (408, 410, 710, 804. 904. 1000, 4218). The removable portion can have an opening with a port (3912, 3916. 4216). The system can also have a container (2812, 3112) configured to contain anticoagulant. The container can have a portion configured to mate with the port of the removable portion. The container can be further configured to not fit into a conventional luer fitting. An anti-coagulant insertion ap...


Title: FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

Publication No: WO2008/140220
Pub. Date - Int. Class - Applicant: - 20.11.2008 - C07D 413/14 - LEGOCHEM BIOSCIENCE LTD.
The present invention relates to novel oxazolidinone derivatives with cyclic araidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa.


Title: METHODS OF MEASURING INHIBITION OF PLATELET AGGREGATION BY THROMBIN RECEPTOR ANTAGONISTS

Publication No: WO2008/137673
Pub. Date - Int. Class - Applicant: - 13.11.2008 - G01N 33/86 - ACCUMETRICS, INC.
A method is provided for measuring inhibition of platelet aggregation by a thrombin receptor antagonist. First, a blood sample is obtained from a patient treated with a thrombin receptor antagonist. The blood sample is mixed in combination with particles including an immobilized GPIIb/IIIa receptor ligand and a thrombin receptor activator. The combination is then incubated under conditions suitable for agglutinating the particles, and platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi in response to the thrombin receptor antagonist treatment. Also provided is a kit for measuring inhibition of platelet aggregation by a thrombin recep...


Title: METHODS FOR MEASURING PLATELET REACTIVITY OF INDIVIDUALS TREATED WITH DRUG ELUTING STENTS

Publication No: WO2008/137600
Pub. Date - Int. Class - Applicant: - 13.11.2008 - G01N 33/86 - ACCUMETRICS, INC.
A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin El (PGEl). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist th...


Title: ANCHORED LIGAND AGENTS

Publication No: WO2008/134069
Pub. Date - Int. Class - Applicant: - 06.11.2008 - C12Q 1/68 - UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
The invention provides novel therapeutic agents comprising ligand molecules such as aptamers linked to a molecular anchor (MA). In the absence of a MA, ligands rapidly diffuse into bulk solution after dissociation from a target molecule. With a MA tightly bound to the target molecule, anchored ligand molecules of the invention remain in close proximity to the active site on the target molecule, even after dissociating from the target, permitting rapid re- binding of ligand to its target. Reversibility of binding to the active site can be effectively and rapidly achieved using antidotes based on the complementary DNA sequences. A preferred embodiment in accordance with the invention is a highly efficient anticoagulant agent that demonstrates...


Title: COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR

Publication No: WO2008/127682
Pub. Date - Int. Class - Applicant: - 23.10.2008 - A61K 31/44 - MILLENNIUM PHARMACEUTICALS, INC.
The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.


Title: CHRONIC ACCESS SYSTEM FOR EXTRACORPOREAL TREATMENT OF BLOOD INCLUDING A CONTINUOUSLY WEARABLE HEMODIALYZER

Publication No: WO2008/082528
Pub. Date - Int. Class - Applicant: - 10.07.2008 - A61M 37/00 - LANDE, Arnold, J.
A patient wearable, continuously operating extracorporeal pump apparatus which accesses the patient's arterial venous pressure differential by applying external pressure to a subcutaneous graft that has been cannualized to modulate blood flow through an extracorporeal circuit and to drive the pump for delivering a medicament, such as an anticoagulant, to the site of an intravenous cannula to prevent clogging thereof and also to move a dialysate through a circuit, including a dialyzer and a dialysate rejuvenating cartridge, whereby kidney failure can be treated without recourse to prior art hemodialysis machines found in most treatment facilities. With slight modification, the present invention can be used to remove excess fluids from CHF pa...


Title: A NANOPARTICLE-BASED ANTICOAGULANT

Publication No: WO2008/063157
Pub. Date - Int. Class - Applicant: - 29.05.2008 - A61K 33/44 - THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
A method for preventing or treating a blood clotting disorder is disclosed. The method includes administering a therapeutic effective amount of at least one nanoparticle-based anticoagulant to a subject afflicted with blood clotting disorder or potentially afflicted with a blood clotting disorder, wherein the at least one nanoparticle-based anticoagulant is a substituted fullerene, polyamidoamine (PAMAM) dendrimer or combination thereof.


Title: ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY

Publication No: WO2008/055145
Pub. Date - Int. Class - Applicant: - 08.05.2008 - A61K 38/17 - THE SCRIPPS RESEARCH INSTITUTE
Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of A...


Title: ANTICOAGULANT COMPOUNDS

Publication No: WO2008/041131
Pub. Date - Int. Class - Applicant: - 10.04.2008 - C07H 11/00 - ENDOTIS PHARMA
The present invention is concerned with anticoagulants (i.e. substances that stop blood from clotting). More specifically, the present invention is concerned with orally available antithrombic oligosaccharides.


Title: METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS

Publication No: WO2007/133665
Pub. Date - Int. Class - Applicant: - 22.11.2007 - A01N 1/02 - TAKEBE, Naoko
An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.


Title: ELECTROSURGICAL INSTRUMENT WITH SUCTION, IRRIGATION AND MEANS TO COLLECT BLOOD

Publication No: WO2007/129321
Pub. Date - Int. Class - Applicant: - 15.11.2007 - A61B 18/18 - BEN SIMHON, Haim
An electrosurgical instrument with electrode, suction, optional irrigation and means to bend the distal part of the surrounding suction tube is described. A distal part of the suction tube (around the electrode) has two members, whereas one member can be engaged inside the other-to various degrees- in order to control the length of the suction tube and its relation to the tip of the electrode. Means to fixate the electrode within the suction tube are described. Also described are means to evacuate smoke, blood, irrigation anticoagulant fluid and debris via a suction tube to a separation chamber and evacuation of the gaseous portions by a vacuum machine. The separation chamber serves as a blood collection container (the blood could then be r...


Title: ADJUSTING PH IN A METHOD OF SEPARATING WHOLE BLOOD

Publication No: WO2007/120962
Pub. Date - Int. Class - Applicant: - 25.10.2007 - A61M 1/36 - GAMBRO BCT, INC.
This invention is directed to a method of collecting and separating whole blood into components. The method includes the steps of adding an anticoagulant having an acidic pH to a bag for collecting and/or separating whole blood, collecting whole blood in the bag, loading the bag containing anticoagulated whole blood on a rotor, spinning the bag on the rotor to separate the whole blood into at least one component; and squeezing the bag on the rotor to push the component from the separation bag into at least one satellite bag.


Title: ANTI-CLOTTING APPARATUS AND METHODS FOR FLUID HANDLING SYSTEM

Publication No: WO2007/120746
Pub. Date - Int. Class - Applicant: - 25.10.2007 - G01N 29/00 - OPTISCAN BIOMEDICAL CORPORATION
Methods and apparatus are provided for determining the concentration of an analyte in a sample, such as an analyte in a sample of bodily fluid. In some embodiments, a method for maintaining clear passageways in an extracorporeal blood flow system includes intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. In some embodiments, an extracorporeal blood flow system includes a passageway and a device operatively connected to provide one or more anti-clotting agents to a least a portion of said passageway.


Title: USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS

Publication No: WO2007/106893
Pub. Date - Int. Class - Applicant: - 20.09.2007 - A61K 38/36 - EMORY UNIVERSITY
The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrat...


Title: PLATELET STABILIZATION

Publication No: WO2007/098436
Pub. Date - Int. Class - Applicant: - 30.08.2007 - A61K 31/197 - SIEMENS HEALTHCARE DIAGNOSTICS INC.
Provided are methods for stabilizing mean platelet component and/or platelets in a sample comprising combining said sample with EDTA, a second anticoagulant, and one or more kinase inhibitors. Also provided are compositions for stabilizing a sample comprising platelets, and kits for storing a platelet sample.


Title: CITRATE ANTICOAGULATION SYSTEM FOR EXTRACORPOREAL BLOOD TREATMENTS

Publication No: WO2007/062197
Pub. Date - Int. Class - Applicant: - 31.05.2007 - A61M 1/36 - EDWARDS LIFESCIENCES CORPORATION
A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.


Title: ANTI-CLOTTING APPARATUS AND METHODS FOR FLUID HANDLING SYSTEM

Publication No: WO2007/044054
Pub. Date - Int. Class - Applicant: - 19.04.2007 - A61M 5/172 - OPTISCAN BIOMEDICAL CORPORATION
A method for maintaining clear passageways in an extracorporeal blood flow system (5000) . The method comprises intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. Also disclosed is an extracorporeal blood flow system. The system comprises a passageway, and a device operatively connected to provide one or more anti-clotting agents to a least a portion of said passageway. The anti-clotting agents can be ultrasound or detergent.


Title: AUTOMATION AND OPTIMIZATION OF CRRT TREATMENT USING REGIONAL CITRATE ANTICOAGULATION

Publication No: WO2007/038347
Pub. Date - Int. Class - Applicant: - 05.04.2007 - A61M 1/16 - EDWARDS LIFESCIENCES CORPORATION
A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added ...


Title: METHOD FOR SEPARATING AND PURIFYING RNA

Publication No: WO2007/026929
Pub. Date - Int. Class - Applicant: - 08.03.2007 - C12N 15/09 - FUJIFILM Corporation
A method for separating and purifying RNA including the steps of passing a sample solution containing a nucleic acid, a washing solution and a recovering solution through a nucleic acid-adsorbing porous membrane to adsorb nucleic acid, adsorbing, washing and recovering, in which the nucleic acid adsorbing porous membrane is a porous membrane capable of adsorbing a nucleic acid by interaction involving substantially no ionic bond, and the sample solution is obtained by a process, comprising the steps of (I) injecting a test sample containing at least one of blood and leukocyte, and further containing an anticoagulant to a container, (II) adding a hemolytic agent to the container to obtain a leukocyte pallet, (III) adding a nucleic acid-solub...


Title: A MACHINE FOR EXTRACORPOREAL BLOOD TREATMENT

Publication No: WO2007/012915
Pub. Date - Int. Class - Applicant: - 01.02.2007 - A61M 1/36 - GAMBRO LUNDIA AB
In a machine for extracorporeal blood treatment, a syringe pump (4) for infusion of an anticoagulant comprises a support (5) for the syringe, a pusher (6), a sensor of the pushing force of the pusher (6), and a control unit (8) for guiding the pusher (6) in accordance with the force measured by the sensor. The support comprises a series of interchangeable gripping elements (9), each of which defines a housing for a syringe having a different diameter, the housing having a longitudinal axis which, for all of the interchageable gripping elements in the series, is always in the same position in relation to the pusher. The invention provides a dialysis machine with a pump that is easily and rapidly adaptable for syringes over a wide range of si...


Title: ANTICOAGULATION AGENT AND USES THEREOF

Publication No: WO2007/003010
Pub. Date - Int. Class - Applicant: - 11.01.2007 - A61K 38/17 - BAKER MEDICAL RESEARCH INSTITUTE
The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.


Title: METHOD AND APPARATUS FOR DETERMINING ANTICOAGULANT THERAPY FACTORS

Publication No: WO2006/122172
Pub. Date - Int. Class - Applicant: - 16.11.2006 - G01N 33/86 - WADA, INC.
Methods and apparatus are disclosed for determining a new anticoagulant therapy factor (nATF) for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. In one embodiment, the new anticoagulant therapy factor is based upon a determination of a new fibrinogen transformation rate (nFTR) which, hi turn, is dependent on a maximum acceleration point (MAP) for fibrinogen (FBG) conversion. The new anticoagulant therapy factor quantity is also based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, but does not require the difficulty of obtaining prior art International Normalized Ratio (INR) and...


Title: ARTIFICIAL BLOOD VESSEL

Publication No: WO2006/085044
Pub. Date - Int. Class - Applicant: - 17.08.2006 - A61F 2/06 - VASCUTEK LIMITED
There is described an artificial blood vessel (1) for use in a region of a living body which needs to be repeatedly pierced with a needle. The artificial blood vessel includes a main section (6) having a vessel wall which includes a laminated assembly (7) comprising an inner layer (3), an outer layer (5), and an intermediate layer (4) positioned therebetween, and a pair of anastomotic sections (2) disposed on the respective opposite ends of the main section. Each of the anastomotic sections has an intermediate layer thinner than the intermediate layer of the main section or is free of an intermediate layer, so that the anastomotic section has a. vessel wall thinner than the main section.


Title: COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING THE SAME

Publication No: WO2006/076401
Pub. Date - Int. Class - Applicant: - 20.07.2006 - A01N 1/02 - BIOVEC, LLC
The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.


Title: METHOD AND SYSTEM FOR DETERMINING PLATELET-MEDIATED CLOT FORMATION

Publication No: WO2006/070346
Pub. Date - Int. Class - Applicant: - 06.07.2006 - G01N 33/49 - RAMOT AT TEL-AVIV UNIVERSITY LTD
The present invention concerns methods for determining platelet medicated clot formation. Specifically, the invention provides a method for determining platelet-medicated clot formation in a blood sample comprising: (i) obtaining sample of blood, and optionally mixing same with an anti-coagulant in an amount effective to inhibit clot formation; (ii) in a vessel, mixing the sample with a minute amount of an initiator to obtain a mixed sample, the amount being effective to initiate coagulation; (iii) rotating the mixed sample inside the vessel, whereby shear forces are developed at the surface of said vessel in a manner and for a time sufficient to allow adhesion of platelets at the surface of said vessel; (iv) determining clot formation at t...


Title: GENETIC VARIANTS OF VKORCI PREDICTING WARFARIN SENSITIVITY

Publication No: WO2006/069339
Pub. Date - Int. Class - Applicant: - 29.06.2006 - C12Q 1/68 - ACADEMIA SINICA
We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the inter­individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.


Title: PROSTHESIS FOR THE NON-INVASIVE TREATMENT OF ANEURYSMS

Publication No: WO2006/067534
Pub. Date - Int. Class - Applicant: - 29.06.2006 - A61F 2/06 - EUROMED CONSULT BT.
The subject of the invention is a prosthesis for the non-invasive treatment of aneurysms and a method for producing the same. The inventive method comprises the steps of taking, with the application of computer tomography known per se, the two- or three- dimensional image of the aneurysm and determining - by means of a three- dimensional CAD application - the thickness and location of the main passage of the prosthesis responsible for sustaining blood flow and, if necessary, the thickness and location of side passages; producing, preferably by means of computer aided manufacturing (CAM) technology and expediently with a 4-axis milling machine, the 1 :1 scale negative shape of the aneurysm and the core pieces providing for the formation of p...


Title: DUAL ANTIPLATELET/ANTICOAGULANT PYRIDOXINE ANALOGS

Publication No: WO2006/050598
Pub. Date - Int. Class - Applicant: - 18.05.2006 - C07D 401/12 - MEDICURE INTERNATIONAL INC.
Pyridoxine analogs , particularly bis-amidine pyridoxine analogs with antiplatelet and anticoagulant characteristics for the treatment of cardiovascular, cerebrovascular and cardiovascular related diseases and symptoms are described. The methods are directed to administering pharmaceutical compositions comprising substituted bis-amidine pyridoxine analogs having the following formulas:(I),(II),(III). wherein at least two of substituents R1- R6 have amidine groups.


Title: ANTICOAGULANT PEPTIDES

Publication No: WO2006/049580
Pub. Date - Int. Class - Applicant: - 11.05.2006 - A61P 7/02 - NATIONAL UNIVERSITY OF SINGAPORE
The present invention provides an isolated peptide having an amino acid sequence of: (a) [S]nNYYYVHQNFDRVAYDYDI[U]m ; or (b) [S]nKIX3X4X5X6KX8X9[U]m, wherein X3, X4 and X8, and are independently an amino acid selected from A, F, I, L, M, V, W and Y; each of X5, X6 and X9 is any amino acid; [S] is any amino acid, and n is an integer from (0) to (15); [U] is any amino acid, and m is an integer from (0) to (15). Further, the use of these peptides as anticoagulants is also provided.


Title: REDUCTION OF COAGULATION IN A BLOOD SAMPLE

Publication No: WO2006/023953
Pub. Date - Int. Class - Applicant: - 02.03.2006 - A61B 5/15 - HONEYWELL INTERNATIONAL INC.
The application sets forth a method for reducing coagulation in a blood sample collected most conveniently from an acral body site such as the fingertip or heel, commonly referred to as capillary blood collection and includes the steps of applying an anticoagulant composition to the acral site, lancing the skin in contact with the anticoagulant composition and allowing blood and anticoagulant to mix on the skin at the site prior to collecting the blood for analysis.


Title: LYSINE CITRATE FOR PLASMA PROTEIN AND DONOR PROTECTION

Publication No: WO2006/012615
Pub. Date - Int. Class - Applicant: - 02.02.2006 - A01N 1/02 - SHANBROM TECHNOLOGIES, LLC
An improved anticoagulant or additive is based on a higher level of citric acid than is usual (at least about 1.0% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits or kills bacteria such as Staphylococcus epidermidis. Collecting blood of plasma into such higher levels of citrate prevents activation of blood proteins so that fractions made from the blood or plasma have superior characteristics.


Title: ANTICOAGULANT CONTRAST MEDIA

Publication No: WO2006/009696
Pub. Date - Int. Class - Applicant: - 26.01.2006 - A61K 49/00 - HEMATROPE PHARMACEUTICALS INC
The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.


Title: SYSTEM AND METHOD FOR TRANSDERMAL DELIVERY OF AN ANTICOAGULANT

Publication No: WO2005/120482
Pub. Date - Int. Class - Applicant: - 22.12.2005 - A61N 1/30 - ALZA CORPORATION
A device for transdermally delivering an anticoagulant agent by electrotransport. Preferably, the anticoagulant comprises a benzamidine or a naphthamidine derivative. A particularly preferred benzamidine derivative is a 2--[3-[4-(4-piperidinyloxy) anilino]-1-propenyl]benzamidine derivative. The devices are configured to maintain a plasma concentration of 20-80 ng/mL or providing a flux in the range of approximately 20 - 40 mg/day. Suitable current densities include 0.050 and 0.10 mA/cm2. Methods of the invention include delivering the anticoagulants to precisely maintain the desired plasma concentrations. The invention also comprises treating thromboembolic disease and inhibiting Factor Xa.


Title: METHODS FOR TREATING BLEEDING DISORDERS USING SULFATED POLYSACCHARIDES

Publication No: WO2005/117912
Pub. Date - Int. Class - Applicant: - 15.12.2005 - A61K 31/727 - AVIGEN, INC.
Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.


Title: DEVICE AND METHODS FOR MONITORING AND REGULATING ANTICOAGULATION THERAPY

Publication No: WO2005/112762
Pub. Date - Int. Class - Applicant: - 01.12.2005 - A61B 5/145 - FLORIDA ATLANTIC UNIVERSITY
A device (100) for determining a dosage of a drug to be administered to a patient is provided. The device includes a sampling module for receiving a sample of patient blood drawn from the patient. Additionally, the device includes a viscosity determining module adjacent to the sampling module for determining a blood viscosity based upon the sample of patient blood. The device further includes a dosage determining module electrically communicating with the viscosity determining module to determine a dosage of the drug to administer to the patient based upon the blood viscosity.


Title: COMPOSITIONS, KIT AND ONE-STEP METHOD FOR MONITORING COMPOUNDS HAVING ANTI-FACTOR XA AND/OR ANTI FACTOR IIA ACTIVITIES

Publication No: WO2005/111231
Pub. Date - Int. Class - Applicant: - 24.11.2005 - C12Q 1/56 - HEPTEST LABORATORIES, INC.
Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation. - - -
- - -
- - -
A PROCESS FOR CONTROLLING AN INFUSION DEVICE.

Publication No: WO2005/102418
Pub. Date - Int. Class - Applicant: - 03.11.2005 - A61M 1/14 - GAMBRO LUNDIA AB
A process comprises the phases of: activating a pusher (10) which exerts a push force on a plunger (9) of a syringe containing the infusion liquid; measuring the push force by mans of a load cell (14); comparing the push force with a maximum threshold; halting the pusher when the maximum threshold is exceeded; after a predetermined pause, restarting the pusher and emitting a consent signal indicating correct loading of the syringe if, within a certain time from the restart, the push force again exceeds the maximum threshold. The infusion device serves to inject an anticoagulant into an extracorporeal blood circuit. The control process guarantees against loss of infusion due to an incorrect initial loading of the syringe.


Title: AN INFUSION DEVICE FOR MEDICAL FLUIDS.

Publication No: WO2005/102417
Pub. Date - Int. Class - Applicant: - 03.11.2005 - A61M 1/14 - GAMBRO LUNDIA AB
The infusion device comprises a pusher for a plunger (10) of a syringe (6) containing a liquid to be infused. A load cell (14) measures the push force. An encoder associated to a motor (13) commanding the pusher measures the displacement of the pusher. A controller (15) signals an alarm when the ratio between the variation of the push force and the displacement exceeds a predetermined threshold. The device, which serves for infusing an anticoagulant into an extracorporeal blood circuit in a dialysis apparatus, is able to signal an onset of an anomalous situation of lack of infusion in good time.


Title: SULFATED OLIGOSACCHARIDE DERIVATIVES

Publication No: WO2005/085264
Pub. Date - Int. Class - Applicant: - 15.09.2005 - A61K 31/7016 - PROGEN INDUSTRIES LIMITED
The invention relates to compounds which are polysufated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.


Title: HEMATOCRIT AND ANALYTE CONCENTRATION DETERMINATION

Publication No: WO2005/054847
Pub. Date - Int. Class - Applicant: - 16.06.2005 - G01N 33/66 - ZAFENA AKTIEBOLAG
A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concen...


Title: METHOD OF ISOLATING AND CULTURING MESENCHYMAL STEM CELL DERIVED FROM UMBILICAL CORD BLOOD

Publication No: WO2005/045010
Pub. Date - Int. Class - Applicant: - 19.05.2005 - C12N 5/06 - HAN, Hoon
The present invention relates to a method of isolating and culturing mesenchymal stem cells using umbilical cord blood that is most ideal for cell therapy. The method comprises adding an anti-coagulant to umbilical cord blood having a volume of more than 45 ml per unit, which is obtained within 24 hours after parturition; diluting the resulting mixture of the anti-coagulant and umbilical cord blood with an aMEM (alpha-minimum essential medium), followed by centrifugation to harvest monocytes; and subjecting the obtained monocytes into suspension culture in the aMEM containing Stem Cell Factor, GM-CSF (granulocyte-macrophage colony-stimulating factor), G-CSF (granulocyte colony-stimulating factor), IL-3 (interleukin-3) and IL-6 (interleuki...


Title: HEPARIN-BINDING PEPTIDES AND USES THEREOF

Publication No: WO2005/014619
Pub. Date - Int. Class - Applicant: - 17.02.2005 - A61K 38/00 - THOMAS JEFFERSON UNIVERSITY
Heparin-binding peptides are provided of the formula R1(X1B1B2X2B3X3YlR2)nR3, R1(X1B1B2B3X2X3B4X4Y1R2)nR3, and C(X1B1B2B3X2X3B4X4)nC; wherein X1, X2, X3, and X4 are independently selected from the group consisting of hydropathic amino acids; B1, B2, B3, and B4 are independently selected from the group consisting of basic amino acids; C is cysteine; Y1 is zero or one to ten amino acid residues, wherein at least one amino acid residue is proline; n is an integer from one to ten; and R1, R2, and R3 are independently selected segments containing from zero to twenty amino acid residues, provided, at least one of the segments R1, R2, and R3 comprises at least one hydrophobic amino acid residue. The peptide C(X1B1B2B3X2X3B4X4)nC is optionally cycl...


Title: A METHOD OF PRODUCING AN ANTICOAGULATION EFFECT

Publication No: WO2005/011724
Pub. Date - Int. Class - Applicant: - 10.02.2005 - A61K 38/00 - CRYPTOME PHARMACEUTICALS LTD
A method for producing an anticoagulation effect in a blood coagulation assay, said method comprising contacting a sample of blood with an effective amount of apolipoprotein CIII or fragment, derivative, homologue, analogue, chemical equivalent, functional equivalent or mimetic thereof.


Title: TRANSDERMAL WARFARIN-CONTAINING DELIVERY SYSTEM

Publication No: WO2005/011644
Pub. Date - Int. Class - Applicant: - 10.02.2005 - A61K 9/70 - ALZA CORPORATION
Composition of matter for application to a body surface or membrane to administer warfarin by permeation through the body surface or membrane, the composition comprising warfarin to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the warfarin or warfarin and enhancer composition and methods for the transdermal administration of the warfarin and warfarin/enhancer composition.


Title: DECORIN PROTEOGLYCAN INHIBITOR OF FIBRINOGEN BLOOD CLOTTING

Publication No: WO2005/011584
Pub. Date - Int. Class - Applicant: - 10.02.2005 - A61K 38/17 - THE TEXAS A &M UNIVERSITY SYSTEM
The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. Fibrin clotting is inhibited by the decorin proteoglycan in a concentration-dependent fashion.


Title: CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS

Publication No: WO2005/007868
Pub. Date - Int. Class - Applicant: - 27.01.2005 - A61K 49/00 - ACCUMETRICS, INC.
A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIlb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is ...


Title: ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY

Publication No: WO2005/007820
Pub. Date - Int. Class - Applicant: - 27.01.2005 - A01N 1/02 - THE SCRIPPS RESEARCH INSTITUTE
Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are 3K3A-APC and 229/230-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include ...


Title: COMPOSITIONS AND METHODS FOR SELECTIVE DISSOLUTION OF NASCENT INTRAVASCULAR BLOOD CLOTS

Publication No: WO2005/004804
Pub. Date - Int. Class - Applicant: - 20.01.2005 - A61K 38/49 - THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.


Title: SUBCUTANEOUS IMPLANTABLE NON-THROMBOGENIC MECHANICAL DEVICES

Publication No: WO2005/004754
Pub. Date - Int. Class - Applicant: - 20.01.2005 - A61F 2/00 - JS VASCULAR, INC.
A mechanical device (10) for implantation into a patient's body is designed or modified to be electrically charged to prevent coagulation on the device, thereby extending the life of the device and alleviating the need for the patient to utilize anticoagulant therapy. The device may be a heart valve and is electrically charged by being connected to a power source (100). The power source is preferably a battery pack (102, 104) implanted in the body and is connected to the device by connector wires (122, 124). The charge applied to the device may be negative or positive, as long as it helps to repel platelets and/or red blood cells from the device in order to help prevent coagulation on one or more surfaces of the device.


Title: A FORMULATION AND A PROCESS FOR REDUCING THE DETERIORATION OF BLOOD WITH PARTICULAR REFERENCE TO DECREASE IN THE LEVEL OF 2,3 DIPHOSPHOGLYCERATE DURING STORAGE

Publication No: WO2004/112630
Pub. Date - Int. Class - Applicant: - 29.12.2004 - A61B 19/00 - TERUMO PENPOL LIMITED
CPDA (citrate-phosphate-dextrose-adenine) solution is the most widely used anti-coagulant preservative solution for collection and storage of whole blood In blood Bags. Even though the permitted period of storage of blood In CPDA solution in 35 days, there is a steady and progressive deterioration in the quality of the blood which increases with storage time. Some of most harmful changes are a drastic decrease in the level of 2,3 diphosphoglycerate (which is essential for delivery of oxygen to the tissues), increased hemolysis (which releases Hb and K+ from the RBCs into the plasma, both of which are harmful) and progressive solubilization of di-(2-ethyl hexyl) phthalate (DEHP), the plasticizer commonly used in the blood Bags which is also ...


Title: STORAGE OF BLOOD

Publication No: WO2004/105483
Pub. Date - Int. Class - Applicant: - 09.12.2004 - A01N 1/02 - BIOENERGY, INC.
D-Ribose, a buffer and an anticoagulant are added to whole blood or packed red cells to extend function in storage beyond 42 days. Methods are disclosed to rejuvenate suboptimally functional red cells. The methods are comprised of incubation of the cells at 37 ° C for 10 to 62 minutes in the presence of D-Ribose.


Title: METHOD FOR DETECTING FILTER CLOGGING BY USING PRESSURE INFORMATION, APPARATUS FOR MONITORING FILTER CLOGGING AND BED-SIDE SYSTEM

Publication No: WO2004/073772
Pub. Date - Int. Class - Applicant: - 02.09.2004 - A61M 1/36 - KONINKLIJKE PHILIPS ELECTRONICS N.V.
A method is provided for detecting filter clogging which are able to keep track of the filter clogging with precision and in detail. At least one pressure selected from the group consisting of a pressure Pa in a blood inflow portion (32a), a pressure Pv in a blood outflow portion (32b), a pressure Pf1 in a filtrate inflow portion (32c), and a pressure Pf2 in a filtrate outflow portion (32d) is measured continuously, then a variation (pressure waveform) of the pressure is analyzed, a clogging of a filter (32) is detected using the analyzed result. Thereby a clogging of a filter is detected early. As a result, it is possible to prevent from developing of the filter clogging by controlling a dosage amount of anti-coagulant properly and changin...


Title: AUTOLOGOUS OR HOMOLOGOUS COAGULANT PRODUCED FROM ANTICOAGULATED WHOLE BLOOD

Publication No: WO2004/068109
Pub. Date - Int. Class - Applicant: - 12.08.2004 - A01N 25/02 - HARVEST TECHNOLOGIES INC
A method for the preparation of a stable autologous or homologous coagulant from whole blood is disclosed. The direct precipitation of anticoagulated whole blood obviates the need for a plasma isolation step with unexpected results. The autologous or homologous coagulant produced by the method of the present invention demonstrated clotting times equivalent to commercially available bovine thrombin and human thrombin preparations, with improved kinetics of growth factor release from activated platelets over preparations of bovine thrombin.


Title: RECONSTITUTABLE DRIED BLOOD PRODUCTS

Publication No: WO2004/057962
Pub. Date - Int. Class - Applicant: - 15.07.2004 - A01N 1/02 - SINVENT AS
The invention provides a process for the preparation of a dried particulate blood product the particles whereof comprise anuclear blood cells in a protective agent, said process comprising: obtaining a blood sample from a mammalian subject; adding an anticoagulant to said sample; concentrating the cells of said sample; recovering a concentrate containing anuclear blood cells from said sample; impregnating with said concentrate a particulate comprising a macromolecular protective material; drying the impregnated particulate at a temperature in the range -20 to +120°C; and, optionally, packaging the dried particulate in sealed containers.


Title: WEARABLE ULTRAFILTRATION DEVICE

Publication No: WO2004/026364
Pub. Date - Int. Class - Applicant: - 01.04.2004 - A61M 37/00 - NATIONAL QUALITY CARE, INC.
An ultrafiltration device (10) adapted to be worn on a portion of the body of a patient includes a blood inlet tube (33) leading from a first blood vessel, a blood pump (60), an anticoagulant reservoir (95) for infusing anticoagulants into the blood, a blood filter (30) including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube (37) leading to a second blood vessel.


Title: ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS

Publication No: WO2004/016267
Pub. Date - Int. Class - Applicant: - 26.02.2004 - A61K 31/00 - BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Disclosed are methods for treating a disease or conditions relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.


Title: POLYMER RESIN FORMULATION HAVING ANTI-MICROBIAL OR ANTI-COGULABILITY AND PREPARATION METHOD THEREOF

Publication No: WO2003/000924
Pub. Date - Int. Class - Applicant: - 31.12.2003 - A61F 2/06 - MICRO SCIENCE TECH CO., LTD.
The present invention relates to an anti-microbial or anti-coagulating polymer resin and a method for preparing the same, and a medical appliance or instrument using the same, and more particularly to a method for preparing an anti-microbial or anti-coagulating medical polymer resin comprising the steps of simply mixing a polymer resin with at least one kind of pharmaceutically active material without using a solvent. The pharmaceutically active material is preferably an anti-microbial or anti-coagulant. According to the present invention, an anti-microbial or anti-coagulating material that is safe to a human body is mixed with a polymer resin by simple addition in an environmentally favorable non-solvent method, thereby maintaining superio...


Title: ANTICOAGULANT COMPOSITION

Publication No: WO2003/000332
Pub. Date - Int. Class - Applicant: - 31.12.2003 - A61K 9/20 - LTP LIPID TECHNOLOGIES PROVIDER AB
A solid heparin tablet composition has a melting point of 25 °C or higher and comprises a continuous lipid component comprising one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the composition, and heparin selected from native heparin and fractionated heparin. Also disclosed is a corresponding tablet, processes for production of the composition and the tablet, and a method of preventing or treating conditions amenable to preventive or therapeutic treatment by administration of the tablet.


Title: NOVEL RECOMBINANT ANTICOAGULANT PROTEINS

Publication No: WO2003/103577
Pub. Date - Int. Class - Applicant: - 18.12.2003 - A61K 38/00 - WUN, Tze, Chein
Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fusions, abbreviated ANV:KPI, utilize ANV having high affinity for phosphatidyl-L-serine with various KPI's to target serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. ANV:KPIs are potentially useful antithrombotic drugs permitting localized passivation of thrombogenic vessel walls and associated thrombi.


Title: RECOMBINANT PROTEIN C VARIANTS

Publication No: WO2003/073980
Pub. Date - Int. Class - Applicant: - 12.09.2003 - A61K 38/00 - T.A.C. THROMBOSIS AND COAGULATION AKTIEBOLAG
The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequence to a wild-type blood coagulation component capable of exhibiting anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC) and activated protein C (APC), said variant component being capable of exhibiting an anticoagulant activity, that is enhanced in comparison with the anticoagulant activity expressed by the corresponding wild-type blood coagulation component, and said variant component differing from the respective wild-type component, in that it contains in comparison with said wild-type component at least one amino acid residue modification in its N-terminal...


Title: SPRAY DRY PROCESS FOR APPLYING ANTICOAGULANT ON A SYRINGE BARREL

Publication No: WO2003/041759
Pub. Date - Int. Class - Applicant: - 22.05.2003 - A61L 33/00 - BECTON, DICKINSON AND COMPANY
A method for coating a substrate surface, such as an interior portion of a syringe is provided. An aqueous anticoagulant solution is atomized onto the substrate surface and dried by the forced flow of warm air. Water is removed during the drying leaving a coating of anticoagulant. A concentrated aqueous anticoagulant solution is used to reduce the time required for drying. A syringe having an interior portion coated with anticoagulant is also provided.


Title: PREVENTION AND TREATMENT OF RESTENOSIS BY LOCAL ADMINISTRATION OF DRUG

Publication No: WO2003/026492
Pub. Date - Int. Class - Applicant: - 03.04.2003 - A61K 38/17 - ESPERION THERAPEUTICS INC.
Apolipoprotein A-I (ApoA-l), preferably a variant form such as Apolipoprotein A-l Milano (ApoA-lM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on diseased coronary, peripheral, and cerebral arteries, surgery to implant grafts or transplanted organs, or angioplasty, or to stabilize unstable plaques. ln an alternative embodiment, the apolipoprotein is not provided directly, but the gene encoding the apolipoprotein is provided. The gene is introduced into the blood vessel in a manner similar to that used for the protein, where the protein is then expressed. The technique can also be used for delivery of genes for treatment or prev...


Title: TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS

Publication No: WO2003/015715
Pub. Date - Int. Class - Applicant: - 27.02.2003 - C07D 221/18 - BRISTOL-MYERS SQUIBB COMPANY
This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa; pharmaceutical compositions containing the same; and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.


Title: PLASMA GLUCOSYLCERAMIDE DEFICIENCY AS RISK FACTOR FOR THROMBOSIS AND MODULATOR OF ANTICOAGULANT PROTEIN C

Publication No: WO2002/102325
Pub. Date - Int. Class - Applicant: - 27.12.2002 - A61K 31/739 - GRIFFIN, John, H.
The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cof...


Title: METHOD TO CARRY OUT DIAGNOSTIC TESTS FROM BLOOD SAMPLE

Publication No: WO2002/097432
Pub. Date - Int. Class - Applicant: - 05.12.2002 - B01L 3/14 - HORSTI, Juha
A method to carry out blood tests from a blood sample (4) and to handle a blood sample, when the blood sample is drawn into a vacuum tube (1) closed with a stopper (2), and in the vacuum tube anticoagulant (3) EDTA is used in connection with the determination of the sedimentation rate. In the method the hematological tests are performed together with the sedimentation test from the sample contained in the same vacuum tube in drawing through stopper (2) a blood sample for hematological tests either before or after determination of the sedimentation rate.


Title: BICYCLIC INHIBITORS OF FACTOR XA

Publication No: WO2002/094197
Pub. Date - Int. Class - Applicant: - 28.11.2002 - C07D 471/04 - BRISTOL-MYERS SQUIBB COMPANY
This invention relates generally to a novel class of bicyclic heterocyclic compounds of the Formula (I), or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.


Title: VASCULAR FILTRATION DEVICE

Publication No: WO2002/089898
Pub. Date - Int. Class - Applicant: - 14.11.2002 - A61M 5/165 - SALEH, Fathy, M., A.
A vascular filtration device for long-term use to filter a bodily fluid in situ is provided. The vascular filtration device includes a channel (10) for being inserted in-line into a bodily fluid transport passageway and allowing the passage of a quantity of bodily fluid therethrough. A filter is disposed within the channel (10) for removing clots or debrits from said quantity of bodily fluid and a sensor (14) is provided for sensing the accumulation of clots and debris on said filter. When clots are detected, the sensor (14) may signal medical professionals that clot removal is necessary, or may automatically trigger the injection of an anticoagulant to dissolve the clots.


Title: WOUND CLOSURE SYSTEM AND METHODS

Publication No: WO2002/089675
Pub. Date - Int. Class - Applicant: - 14.11.2002 - A61B 17/00 - BIOINTERACTIONS LTD.
A wound closure system and methods utilizes a patient's own blood. The system preferably includes a chamber with a needle and a plunger for transferring and storing blood prior to surgery and the use of reversible anticoagulants. The chamber is pre-loaded with a reversible anticoagulant to prevent the blood from clotting during storage. When the surgery is complete, a counteracting agent is mixed with the withdrawn blood to counteract the reversible anticoagulant and allow the blood to clot. The clottable blood is then reintrduced into the patient to close a wound.


Title: SYSTEM FOR THE PRODUCTION OF AUTOLOGOUS PLATELET GEL

Publication No: WO2002/080991
Pub. Date - Int. Class - Applicant: - 17.10.2002 - A61L 24/00 - MEDTRONIC, INC.
A centrifuge system is disclosed for the formation of an autologous platelet gel wherein all of the blood components for the gel are derived from a patient to whom the gel is to be applied. First a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma or platelet poor plasma is then automatically drawn out of the centrifuge bag and proportioned into separate chambers in a dispenser. The first portion is activated where a clot is formed and thrombin is obtained. The thrombin is then latter mixed with the second portion to obtain a platelet gel. Delivery systems are mentioned.


Title: FUSED HETEROCYCLIC INHIBITORS OF FACTOR XA

Publication No: WO2002/080853
Pub. Date - Int. Class - Applicant: - 17.10.2002 - C07D 401/04 - BRISTOL-MYERS SQUIBB COMPANY
This invention relates generally to a novel class of fused heterocyclic compounds of the Formula (I) or Formula (II): or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.


Title: RAPID ASSESSMENT OF COAGULATION ACTIVITY IN WHOLE BLOOD

Publication No: WO2002/079375
Pub. Date - Int. Class - Applicant: - 10.10.2002 - C12Q 1/56 - COAGULATION DIAGNOSTICS, INCORPORATED
The present invention is directed to methods to rapidly assess the overall coagulant properties of a patient's blood sample by inhibiting the activation of the intrinsic contact activation pathway of coagulation and activating the extrinsic pathway of coagulation. When the sample is whole blood, the resulting clotting time represents the overall coagulant activity of the plasma and cellular components of the blood, which is indicative of existing or impending pathology arising from abnormal coagulability. The invention also provides a method for measuring the risk of a patient for a thrombotic event and for monitoring the effectiveness of procoagulant/anticoagulant therapy. A blood collection apparatus suitable for use in for performing the...


Title: PROTEIN C VARIANTS

Publication No: WO2002/070681
Pub. Date - Int. Class - Applicant: - 12.09.2002 - A61K 38/00 - T.A.C. THROMBOSIS AND COAGULATION AB
The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequence to a wild-type blood coagulation component capable of exhibiting anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC) and activated protein C (APC), said variant component being capable of exhibiting an anticoagulant activity, that is enhanced in comparison with the anticoagulant activity expressed by the corresponding wild-type blood coagulation component, and said variant component differing from the respective wild-type component, in that it contains in comparison with said wild-type component at least one amino acid residue modification in its N-terminal...


Title: MONITORING SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR LEVELS IN ANTICOAGULANT THERAPY

Publication No: WO2002/066981
Pub. Date - Int. Class - Applicant: - 29.08.2002 - G01N 33/68 - OKLAHOMA MEDICAL RESEARCH FOUNDATION
The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patents or normal individuals can also be identified by such an assay.


Title: POST-PARTUM MAMMALIAN PLACENTA, ITS USE AND PLACENTAL STEM CELLS THEREFROM

Publication No: WO2002/064755
Pub. Date - Int. Class - Applicant: - 22.08.2002 - A61K 35/12 - ANTHROGENESIS CORPORATION
The present invention provides a method of extracting and recovering embryonic like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to move residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem ce...


Title: FACTOR IXA: FACTOR VIIIA INTERACTION AND METHODS THEREFOR

Publication No: WO2002/059268
Pub. Date - Int. Class - Applicant: - 01.08.2002 - A61K 38/00 - SAINT LOUIS UNIVERSITY
Novel agents that inhibit the interaction of factor VIIIa with factor IXa in newly discovered regions of interaction, Region 2 and Region 3, are disclosed. The novel polypeptides or derivatives of polypeptides prevent activation of factor X and have anti-coagulation activity. The agents include polypeptides or polypeptide derivatives that are homologous to factor VIIIa or factor IXa in Region 2 and/or Region 3, as well as agents that are not homologous, such as antibodies that bind to factor VIIIa or factor IXa in Region 2 or Region 3. Pharmaceutical compositions comprising the agents are also disclosed. Methods of treatment are also disclosed, comprising the step of determining whether the compound displaces the interaction of the above ag...


Title: COMPOSITIONS FOR PRESERVATION OF ORGANS AND BLOOD

Publication No: WO2002/049653
Pub. Date - Int. Class - Applicant: - 27.06.2002 - A01N 1/02 - METABOLIC ENGINEERING LABORATORIES CO., LTD.
The present invention relates to compositions for the preservation of organs and blood. More particularly, it relates to a composition for the preservation and storage of organs, which comprises macromolecules in an amount sufficient to inhibit cell swelling; a buffer in an amount sufficient to perform a buffering function to the range of physiological pH; an energy source in an amount sufficient to maintain bio-energy; magnesium ions in an amount sufficient to maintain bio-energy; and an aldehyde-removing agent in an amount sufficient to remove intracellular aldehydes. Also, it relates to a composition for the preservation and storage of blood, which comprises mannitol in an amount sufficient to inhibit haemolysis; a buffer in an amount su...


Title: METHOD OF COLLECTING PLACENTAL STEM CELLS

Publication No: WO2002/046373
Pub. Date - Int. Class - Applicant: - 13.06.2002 - A61K 48/00 - HARIRI, Robert, J.
A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.


Title: METHOD FOR PRECIPITATING RED BLOOD CELLS

Publication No: WO2002/045569
Pub. Date - Int. Class - Applicant: - 13.06.2002 - A61M 1/36 - HARVEST TECHNOLOGIES CORPORATION
A method for washing collected blood uses an inert anticoagulant during collection of the blood. The inert anticoagulant does not interfere with agglomeration of the red blood cells so that gravity sedimentation separation is facilitated. The preferred inert anticoagulant is CPD.


Title: FGF-AFFINITY CHROMATOGRAPHY

Publication No: WO2002/042336
Pub. Date - Int. Class - Applicant: - 30.05.2002 - A61K 38/00 - THE TEXAS A &M UNIVERSITY SYSTEM
The present invention relates to a method and apparatus for isolating anticoagulant heparin or heparan sulfate by binding the anticoagulant heparin or anticoagulant heparan sulfate onto an affinity matrix and separating the non-bound material from the bound material. The affinity matrix is made of a fibroblast growth factor immobilized on a support. The invention also relates to a method and composition for neutralizing anticoagulant catalyzed by heparin, a heparin mimic, or a heparin derivative, by contacting heparin, a heparin mimic, or a heparin derivative with a fibroblast growth factor.


Title: METHOD OF MEASURING PLATELET ACTIVATION

Publication No: WO2002/039124
Pub. Date - Int. Class - Applicant: - 16.05.2002 - G01N 33/86 - BARTS AND THE LONDON NHS TRUST
Platelet activation is measured by determining Mean Platelet Component (MPC) of suspended blood platelets, using a specific anticoagulant composition. The composition comprises at least one component for effecting platelet sphering (for example EDTA), and at least one platelet antagonist (for example at least one of, and preferably all three of theophylline, adenosine and dipyridamole).


Title: PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND DIAGNOSIS OF TUMORS AND METHOD FOR THE PREPARATION OF THE LIPID FREE FRACTION OF BLOOD PLASMA

Publication No: WO2002/007739
Pub. Date - Int. Class - Applicant: - 31.01.2002 - A61K 35/16 - BERTHA, András
Pharmaceutical preparation for the treatment and follow-up care of tumors that comprises the blood plasma or predetermined blood plasma components of equidae animals with pair number of fingers, preferably cattle being not endangered lethally by leucosis . The predetermined fraction is the material 'bovin 40' and/or 'bovin 300' constituting the difference detectable by electrophoresis between the lipid-free fraction taken from a healthy cattle. In the separation method of the required fraction the initial blood is optionally treated by an anti-coagulant and the corpuscles are separated therefrom, the plasma fraction is treated by a first organic solvent, then a surfactant material composed of fine grains is added thereto, the liquid is mixe...


Title: INHIBITION OF TUMOR GROWTH BY A NEMATODE ANTICOAGULANT PROTEIN

Publication No: WO2002/004010
Pub. Date - Int. Class - Applicant: - 17.01.2002 - A61K 35/56 - ENTREMED, INC.
The present invention relates to compositions and uses of nematode anticoagulant proteins (NAPs). More specifically, the invention relates to the use of rNAPc2 and rNAP5 for the inhibition of endothelial cell proliferation and the inhibition of angiogenesis. The invention also relates to methods for the treatment of angiogenesis-mediated diseases, such as cancer.


Title: METHOD AND APPARATUS FOR LOCKING OF CENTRAL-VEIN CATHETERS

Publication No: WO2001/097881
Pub. Date - Int. Class - Applicant: - 27.12.2001 - A61M 5/19 - TWARDOWSKI, Zbylut, J.
A central-vein catheter (10) is locked by anticoagulant (15) and bactericidal (17) agents separated by an air bubble (16). The anticoagulant (15) is injected first, then the air bubble (16), and then the bactericidal solution (17). The air bubble (16) prevents mixing of the solutions. A multi-chamber syringe (20) facilitates sequential injection of the coagulant (15), air (16) and bactericidal agent (17) with only one connection, decreasing chances of contamination. The syringe (20) includes internal (30) and external (21) coaxial barrels separated by seals (29), the external barrel (21) having a discharge opening (26) located off center in the barrel bottom, and the internal barrel having two or three chambers, each with an outlet opening....


Title: A FAIL-SURE COMPUTER AIDED METHOD FOR ANTICOAGULANT TREATMENT

Publication No: WO2001/093762
Pub. Date - Int. Class - Applicant: - 13.12.2001 - A61B 5/00 - MEDIMAGE APS
The present invention relates to a method for determining a set of corresponding dose of a drug and time to take the drug. The method comprises the step of measuring a blood coagulation value at a patient and by use a first computer system determining the set of corresponding dose and time to take the drug. The determination by use of the computer system is also preferably performed at the patient. Furthermore, the present invention relates to a validation method in which data relating to the determination of the set of corresponding dose and time to take the drug is transmitted to a second computer system. By use of this second computer system a set of corresponding dose and time to take the drug is determined and this set may be validated...


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/087854
Pub. Date - Int. Class - Applicant: - 22.11.2001 - A61K 38/00 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/087852
Pub. Date - Int. Class - Applicant: - 22.11.2001 - C07D 239/545 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl uracil compounds of formula (I) useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/087851
Pub. Date - Int. Class - Applicant: - 22.11.2001 - C07D 239/47 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl pyrimidinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/087842
Pub. Date - Int. Class - Applicant: - 22.11.2001 - C07D 213/74 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds of the formula (I) useful as inhibitors of serine protease of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: A CATHETER LOCK SOLUTION INCLUDING A PHOTO-OXIDANT

Publication No: WO2001/085249
Pub. Date - Int. Class - Applicant: - 15.11.2001 - A61L 29/14 - ASH MEDICAL SYSTEMS, INC.
This invention relates to compositions, methods and devices relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods and devices aid in diminishing the effects of infection in the catheters and occlusion of the catheters. An inventive lock solution includes an anticoagulant and a photo-oxidant, and preferably has a density suitable for retention of the solution in a catheter during the lock period.


Title: METHOD AND APPARATUS FOR DOSAGE OF AN ADDITIVE WHILE COLLECTING A LIQUID

Publication No: WO2001/083004
Pub. Date - Int. Class - Applicant: - 08.11.2001 - A61M 1/00 - BST BLOOD SAVING TECHNOLOGIES AB
The invention relates to a method and an apparatus for collecting and transporting liquids, for instance blood, while at the same time dosing an additive, for instance an anticoagulent agent, in an accurate proportion to the amount of the collected liquid. The liquid or a liquid/air/gas mixture is sucked up by means of a suction nozzle (4) and transported through a suction hose (5). A dosage device (6) comprising an exchangeable, flexible container (23) with said dosing additive, for instance a CPD bag, is connected to the suction hose whereby the pressure levels in the apparatus, provided by connecting the apparatus to a vacuum pump (1), are adjusted in such a way relative to each other that no additive at all is introduced when only air/g...


Title: POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 1,4-QUINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/079155
Pub. Date - Int. Class - Applicant: - 25.10.2001 - C07C 257/18 - PHARMACIA CORPORATION
The invention relates to polycyclic aryl and heteroaryl substituted 1,4-quinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/077097
Pub. Date - Int. Class - Applicant: - 18.10.2001 - C07D 309/38 - PHARMACIA CORPORATION
The invention relates to polycyclic aryl and heteroaryl substituted 4-pyrone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/077079
Pub. Date - Int. Class - Applicant: - 18.10.2001 - C07D 213/74 - PHARMACIA CORPORATION
The invention relates to polycyclic aryl and heteroaryl substituted 4-pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: THE USE OF ANTICOAGULANT AGENTS IN THE EXTRACORPOREAL TREATMENT OF BLOOD

Publication No: WO2001/070273
Pub. Date - Int. Class - Applicant: - 27.09.2001 - A61K 47/48 - KNOLL GMBH
The present invention relates to the use of anticoagulant agents, and in particular of PEG-hirudin, for treating individuals with extracorporeal circulation for prophylaxis of vascular complications after the extracorporeal circulation. It is thus possible in particular to treat individuals with chronic renal insufficiency requiring regular hemodialysis and moreover prevent vascular complications which conventionally result in a high morbidity and mortality rate for dialysis patients treated longer-term.


Title: POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2001/068605
Pub. Date - Int. Class - Applicant: - 20.09.2001 - C07C 257/18 - PHARMACIA CORPORATION
The invention relates to polycyclic aryl and heteroaryl substituted benzene compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: EXTRACORPOREAL BLOOD PROCESSING METHOD AND APPARATUS

Publication No: WO2001/066172
Pub. Date - Int. Class - Applicant: - 13.09.2001 - A61M 1/36 - GAMBRO, INC.
Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extracorporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell c...


Title: FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF

Publication No: WO2001/055146
Pub. Date - Int. Class - Applicant: - 02.08.2001 - C07C 257/18 - LG CHEM INVESTMENT LTD.
The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders.


Title: MULTIPLE INACTIVATED BLOOD FACTOR ANTICOAGULANT COMPOSITION

Publication No: WO2001/051067
Pub. Date - Int. Class - Applicant: - 19.07.2001 - A61K 38/48 - BAXTER INTERNATIONAL INC.
An anticoagulant composition is provided which comprises at least two inactivated blood factors in a pharmaceutically acceptable carrier, such inactivated blood factors being present in a therapeutically effective dosage. Methods for utilizing such anticoagulant compositions comprising providing to a patient a coagulation inhibiting amount thereof are also provided, as are methods for the preparation of such compositions.


Title: APPARATUS AND METHODS FOR MONITORING AND MODIFYING ANTICOAGULATION THERAPY OF REMOTELY LOCATED PATIENTS

Publication No: WO2001/050950
Pub. Date - Int. Class - Applicant: - 19.07.2001 - A61B 5/00 - ZYCARE, INC.
A patient apparatus is configured to receive and analyze information regarding patient compliance with anticoagulation medication and self-test coagulation regimens related to anticoagulation therapy. In addition, a patient apparatus is configured to receive data from a patient, including physiological data, pathophysiological data, biological data, psychological data, neuropsychological data, and/or behavioral data. Utilizing the received patient data, a patient apparatus can modify a warfarin regimen using an algorithm contained within the apparatus. The apparatus can communicate the modified warfarin regimen to the patient and to third parties, such as remotely located healthcare providers. In addition, the apparatus can prompt a patient...


Title: METHOD FOR DETECTING, TREATING, AND MONITORING CONDITIONS ASSOCIATED WITH ACTIVATION OF THE COAGULATION RESPONSE

Publication No: WO2001/012839
Pub. Date - Int. Class - Applicant: - 22.02.2001 - C12Q 1/68 - BERG, David, E.
Methods for diagnosing, treating and monitoring conditions associated with activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of fibrinogen, prothrombin fragment 1 + 2, thrombin/antithrombin complexes and soluble fibrin monomers. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.


Title: METHOD FOR MEASURING COAGULANT FACTOR ACTIVITY IN WHOLE BLOOD

Publication No: WO2001/007070
Pub. Date - Int. Class - Applicant: - 01.02.2001 - C12Q 1/56 - THE SCRIPPS RESEARCH INSTITUTE
The present invention is directed to methods to rapidly assess the overall coagulant properties of a patient's blood sample by measuring and comparing clotting time with and without an added inhibitor of a procoagulant or an anticoagulant. When the sample is whole blood, the resulting clotting time represents the overall coagulant activity of the plasma and cellular components of the blood, which is indicative of existing or impending pathology arising from abnormal coagulability. The invention also provides a method for measuring the risk of a patient for a thrombotic event by determining functionally current levels of one or more procoagulants or anticoagulants in whole blood. In addition, a method for measuring the effectiveness of antic...


Title: EXTENDING THE LIFETIME OF ANTICOAGULANT OLIGODEOXYNUCLEOTIDE APTAMERS IN BLOOD

Publication No: WO2000/078364
Pub. Date - Int. Class - Applicant: - 28.12.2000 - A61K 47/48 - THE UNIVERSITY OF ALBERTA; SIMON FRASER UNIVERSITY; THE UNIVERSITY OF VICTORIA; THE UNIVERSITY OF BRITISH COLUMBIA DOING BUSINESS AS TRIUMF
The present invention is a complex of a polynucleotide having a property of specifically binding to a target protein together with a protein that stabilizes the polynucleotide from degradation and from clearance from the circulation in vivo. Methods for diagnostic imaging and therapeutic uses of the complex are disclosed.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2000/069834
Pub. Date - Int. Class - Applicant: - 23.11.2000 - C07D 241/20 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS

Publication No: WO2000/069833
Pub. Date - Int. Class - Applicant: - 23.11.2000 - C07D 239/545 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl uracil compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS

Publication No: WO2000/069832
Pub. Date - Int. Class - Applicant: - 23.11.2000 - C07D 239/46 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl pyrimidinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Publication No: WO2000/069826
Pub. Date - Int. Class - Applicant: - 23.11.2000 - C07D 213/74 - PHARMACIA CORPORATION
The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds having Formula (I) or a pharmaceutically acceptable salt thereof, wherein: a.o., $g(C) is selected from the group consisting of NH and NOH; useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.


Title: A PEPTIDE INHIBITOR OF FIBRINOGEN BLOOD CLOTTING

Publication No: WO2000/068264
Pub. Date - Int. Class - Applicant: - 16.11.2000 - A61K 38/00 - THE TEXAS A &M UNIVERSITY SYSTEM
A method of inhibiting fibrin clot formation is provided. The decorin protein, peptide, or related fragments are found to bind fibrinogen in the presence of Zinc (Zn?2+ż), thus preventing the formation of fibrin clots. The decorin protein, peptide, or related fragments can be utilized as an anticoagulant and in methods of preventing and/or treating diseases and disorders characterized by clot formation.


Title: SUBSTITUTION INFUSION FLUID AND CITRATE ANTICOAGULATION

Publication No: WO2000/064456
Pub. Date - Int. Class - Applicant: - 02.11.2000 - A61K 33/42 - CHANG, Pe, Chou
The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing hemofiltration. The invention also relates to a process for hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a citrate anticoagulation fluid of a specific composition. The invention also relates to a process for hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly furthe...


Title: AUTOLOGOUS FIBRIN SEALANT AND METHOD FOR MAKING THE SAME

Publication No: WO2000/062828
Pub. Date - Int. Class - Applicant: - 26.10.2000 - A61L 24/00 - MEDTRONIC, INC.
In general, the present invention relates to a two-phase method for forming an autologous bioadhesive sealant composition or fibrin glue wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. First, a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma and platelet poor plasma are then divided into two portions. To the first portion, which is used in phase-one, a compound that revearses the effect of the anticoagulant is added, and a clot is allowed to form. The clot is then triturated and the resulting serum, containing autol...


Title: METHOD AND APPARATUS FOR PRODUCING PLATELET RICH PLASMA AND/OR PLATELET CONCENTRATE

Publication No: WO2000/061256
Pub. Date - Int. Class - Applicant: - 19.10.2000 - A61M 1/02 - HARVEST TECHNOLOGIES CORPORATION
Platelet rich plasma and/or platelet concentrate is prepared by placing whole blood in a first chamber (6) of a sterile processing disposable having two chambers (6, 8). The processing disposable is subjected to a first centrifugation to separate red blood cells (36), and the resulting platelet rich plasma supernatant (38) is decanted to the second chamber (8). The processing disposable is subjected to a second centrifugation to concentrate platelets. A volume of the platelet poor plasma supernatant in the second chamber (8) is removed, and the platelets are re-suspended in the remaining plasma. The second chamber (8) may contain anticoagulant (34) to preclude aggregation of the platelets.


Title: DIAGNOSTIC TEST FOR THE MEASUREMENT OF ANALYTE IN A BIOLOGICAL FLUID

Publication No: WO2000/044930
Pub. Date - Int. Class - Applicant: - 03.08.2000 - C12Q 1/52 - ABBOTT LABORATORIES
A biosensor for determining the concentration of an analyte, such as, for example, ALT, in a sample of biological fluid, such as, for example, whole blood, comprising: (a) a base layer; (b) a detecting layer comprising a reference electrode and a working electrode, the surface of the electrically conductive portion of the working electrode being sufficiently smooth so that determination of the concentration of an analyte present in a low concentration, e.g. less than 1 mM, can be made; (c) a layer overlying said electrodes, said layer comprising dried reagents; and (d) an anticoagulant disposed in such a location that it will prevent the sample from coagulating during the determination. The biosensor preferably further includes a fluid-tran...


Title: ANTI-COAGULATION WITH CALCIUM CONTAINING CITRATE SOLUTION

Publication No: WO2000/033853
Pub. Date - Int. Class - Applicant: - 15.06.2000 - A61K 35/14 - GLOBAL HEMOSTASIS INSTITUTE MGR AB
A method of anti-coagulating a blood product and counteracting the reduction of calcium ion activity in the anti-coagulated product, is disclosed. The method comprises addition to the blood product of an anti-coagulant selected from the group consisting of soluble citrate compounds, citric acid, and mixtures thereof in an amount of 13-60 mmole citrate per liter of anti-coagulated blood product, and of a soluble calcium compound in an amount giving a calcium ion activity in the anti-coagulated blood product of 0.2 - 10mM. Further, an anti-coagulated blood or blood plasma product comprising such an anti-coagulant and calcium compound, and its use for the production of coagulation Factor VIII, are described. Additionally, a blood sampling cont...


Title: HETEROCYCLIC COMPOUNDS REGULATING CLOTTING

Publication No: WO2000/030646
Pub. Date - Int. Class - Applicant: - 02.06.2000 - A61K 31/5365 - NOVO NORDISK A/S
The invention relates to the use of heterocyclic compounds with formulas (I) and (II), and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for treatment of coagulation-related diseases. The compounds are inhibitors of TF-FVIIa activity and thus show anticoagulant activity. The invention also relates to methods of treatment. The invention furthermore relates to novel compounds with the formula (I) or (II).


Title: AUTOMATIC WHOLE BLOOD COLLECTION SYSTEM

Publication No: WO2000/021590
Pub. Date - Int. Class - Applicant: - 20.04.2000 - A61M 1/02 - HAEMONETICS CORPORATION
A whole blood collection system includes an automated pump/control unit and an accompanying disposable blood set. When combined and connected to a source of anticoagulant, these elements allow automatic priming of the blood set with anticoagulant and automatic collection of anticoagulated blood product according to three different collection modes. The unit's pump and the blood set are specially designed to cooperate during the collection process to assure that the collected product has a precise blood to anticoagulant ratio. During the collection procedure, the pump/control unit automatically collects data relating to the procedure. Additional data specifically identifying components of the blood set, such as the blood collection bag, alon...


Title: METHOD AND APPARATUS FOR DETERMINING ANTICOAGULANT THERAPY FACTORS

Publication No: WO2000/007012
Pub. Date - Int. Class - Applicant: - 10.02.2000 - G01N 33/49 - CARROLL, Wallace, E.
A method and apparatuses are disclosed for determining an anticoagulant therapy factor (ATF), a corrected anticoagulant therapy factor and a modified anticoagulant therapy factor, all selectively used for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The anticoagulant therapy factor, the corrected anticoagulant therapy factor, and a modified anticoagulant therapy factor are based upon disclosed methods for determining the fibrinogen tranformation rate which, in turn, is dependent on a maximum acceleration point for fibronogen conversion.


Title: LUPUS ANTICOAGULANT ANTIBODY TO F1 REGION OF PROTHROMBIN

Publication No: WO2000/002925
Pub. Date - Int. Class - Applicant: - 20.01.2000 - A61K 39/00 - GRADIPORE LIMITED
Isolated antibodies directed against the F1 region of prothrombin, which antibodies mimic the effect of a lupus anticoagulant (LA) $i(in vitro), and uses of the antibodies in blood clotting tests.


Title: ANTIMICROBIAL LOCKS COMPRISING TAURINAMIDE DERIVATIVES AND CARBOXYLIC ACIDS AND/OR SALTS THEREOF

Publication No: WO2000/001391
Pub. Date - Int. Class - Applicant: - 13.01.2000 - A61K 31/18 - BIOLINK CORPORATION
The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically affective amount of a composition comprising: (A) at least one taurinamide derivative, and (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anticlotting and no systemic biocidal effects.


Title: AMPHIPHILIC POLYSACCHARIDE DERIVATIVES

Publication No: WO1999/061481
Pub. Date - Int. Class - Applicant: - 02.12.1999 - A61K 31/727 - MEDIPLEX CORPORATION, KOREA
Polysaccharides, which are widely used as anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic heparin derivatives were synthesized by conjugate to bile acids, sterols, and alkanoic acids, respectively. The hydrophobicity of the heparin derivatives depended on the feed mole ratio of heparin to hydrophobic agent. The heparin derivatives were slightly hydrophobic and exhibited good solubility in a water-acetone solvent, as well as water. The heparin derivatives have a high anticoagulant activity. These slightly hydrophobic heparin derivatives can be absorbed in gastric intestinal tract and can be used as...


Title: COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF UNCONTROLLED FORMATION OF INTRAVASCULAR FIBRIN CLOTS

Publication No: WO1999/059611
Pub. Date - Int. Class - Applicant: - 25.11.1999 - A61K 38/16 - THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.


Title: HETEROCYCLIC COMPOUNDS REGULATING CLOTTING

Publication No: WO1999/048878
Pub. Date - Int. Class - Applicant: - 30.09.1999 - A61K 31/536 - NOVO NORDISK A/S
The use of compounds of general formula (I) as factor VII-tissue factor inhibitors as well as novel benzoaxin derivatives are disclosed. The compounds of general formula (I) and pharmaceutical acceptable salts thereof have been shown to be inhibitors of factor VIIa-tissue factor activity. The compounds show anticoagulant properties. The compounds are useful for the treatment of deficiencies of blood clotting factors or the effects of inhibitors to blood clotting factors. Methods for inhibiting clotting activity are disclosed.


Title: SCREENING FOR BLOOD COAGULATION DEFECTS USING METAL IONS

Publication No: WO1999/047699
Pub. Date - Int. Class - Applicant: - 23.09.1999 - C12Q 1/56 - CHROMOGENIX AB
In vitro photometric method for qualitative screening and quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation, comprising measuring the conversion rate of an exogenous substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said exogenous substrate after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions; and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way, comprising adding further metal(s) ions to said s...


Title: ANTICOAGULANT INTERNALLY COATED NEEDLE

Publication No: WO1999/047037
Pub. Date - Int. Class - Applicant: - 23.09.1999 - A61B 5/15 - SIMS PORTEX INC.
To prevent the dilution effect that causes inaccuracy in the measurement of the characteristics of blood drawn from a patient, a needle assembly (2) has the interior portion of its cannula (6) and at least one portion of its hub (4) covered by a dry coat of anticoagulant. To provide the dry coat of anticoagulant onto the interior surfaces of the cannula (6) and the hub (4), a liquid anticoagulant is atomized thereto so that an even coat of the anticoagulant is provided to the interior surfaces of the cannula and hub. The volume and concentration of the anticoagulant atomized to the inside of the needle assembly are controlled as the liquid anticoagulant is ultra-sonically atomized to the interior portion of the needle assembly.


Title: APHERESIS SYSTEM WITH ANTICOAGULANT FLOW CONTROL

Publication No: WO1999/045995
Pub. Date - Int. Class - Applicant: - 16.09.1999 - A61M 1/36 - BAXTER INTERNATIONAL INC.
An apheresis system (10) is disclosed which may include a separation chamber (20); a suspension flow path which communicates at one end with the separation chamber and includes a connector (16) at the other end for connecting to a source of cellular suspension; an anticoagulant flow path which communicates at one end with the suspension flow path and includes a connector (26) at the other end for connecting to an anticoagulant source (22); and a return flow path which communicates at one end with the separation chamber and communicates at the other end with a connector (18) for connection directly to the suspension source or to the suspension flow path for returning one or more suspension components to the source. The anticoagulant flow pat...


Title: METHOD FOR PERFORMING BLOOD CELL COUNTS

Publication No: WO1999/045386
Pub. Date - Int. Class - Applicant: - 10.09.1999 - G01N 15/05 - WARDLAW, Stephen, C.
A method for evaluating constituents of a sample of substantially undiluted anti-coagulated whole blood is provided which includes the steps of: a) providing a sample chamber (10); b) admixing a sensible colorant with the sample of whole blood; c) inserting the admixed sample into the sample chamber; d) quiescently holding the admixed sample for a period until rouleaux (30) and lacunae (32) form within the sample; and e) evaluating a target constituent disposed within the lacunae (32).


Title: DETERMINATION OF WHITE BLOOD CELL DIFFERENTIAL AND RETICULOCYTE COUNTS

Publication No: WO1999/045384
Pub. Date - Int. Class - Applicant: - 10.09.1999 - G01N 15/00 - WARDLAW, Stephen, C.
Target nucleated cells, and target cells containing remanant ribosomal material, which are present in a quiescent anticoagulated whole blood sample are optically detected, enumerated, and analyzed in a sample chamber (14) that has a varying through plane thickness due to convergent opposing sample chamber walls. At least one of the convergent walls (8) of the chamber is transparent so that the blood sample can be observed. The chamber's varying thickness produces a first lesser thickness region (A) in the chamber wherein individual red cells (32) and quiescent monolayers (31) of red cells in the sample will reside after the sample is introduced into and fills the chamber. Larger formed constituents such as white blood cells (34) and nucleat...


Title: METHOD OF MEASURING ERYTHROCYTE SEDIMENTATION RATE (ESR) OR PLASMA FIBRINOGEN OF A BLOOD SAMPLE

Publication No: WO1999/045363
Pub. Date - Int. Class - Applicant: - 10.09.1999 - G01N 15/04 - ZYNOCYTE LIMITED
There is provided a method of measuring erythrocyte sedimentation rate (ESR) or plasma fibrinogen in a blood sample. The method involves treating the blood sample with a suitable anti-coagulant, placing the treated sample in a micro-haematocrit tube and centrifuging the sample at, for example, 500 rpm or greater whilst continually monitoring the sample using an IR light source and detector to follow appropriate separation band development during centrifugation. Thus, continual monitoring of the sample during the centrifugation process is possible. Desirably, the sample is horizontal throughout the centrifugation process.


Title: ANALYSIS OF QUIESCENT ANTICOAGULATED WHOLE BLOOD SAMPLES

Publication No: WO1999/044593
Pub. Date - Int. Class - Applicant: - 10.09.1999 - G01N 15/00 - WARDLAW, Stephen, C.
Formed constituents of a quiescent anticoagulated whole blood sample are optically of visually analyzed in a sample chamber (14) which has a varying through plane thickness due to convergent opposing sample chamber walls (4, 8). At least one of the convergent walls of the chamber is transparent so that the blood sample constituents can be observed. The chamber's varying thickness produces a first lesser thickness region (A) in the chamber wherein a quiescent monolayer of red blood cells in the sample will reside after the sample is introduced into and fills the chamber. Larger formed constituents such as white blood cells in the sample are unable to enter the aforesaid lesser thickness region of the chamber. The red cells which reside in th...


Title: PROSTHETIC HEART VALVE

Publication No: WO1999/026560
Pub. Date - Int. Class - Applicant: - 03.06.1999 - A61F 2/24 - CARDIOTECH INTERNATIONAL CORPORATION
Bileaflet heart valves are illustrated which employ a pair of leaflets having flat inflow and outflow surfaces that are nonparallel to each other with the downstream arcuate edges being thinner than the mating upstream edges. The pivot mechanisms are constructed so that the leaflet inflow surfaces can be oriented parallel to the centerline through the valve body in the full open position, with the offset outflow surfaces constituting a diffuser section which provides for pressure recovery and reduces overall pressure drop through the valve. The pivot structures are preferably generally ellipsoidal in shape, with the long axis of the ellipsoid being aligned generally in an upstream-downstream direction. This feature together with the offset ...


Title: SYSTEM AND METHOD FOR MEASURING A BIOANALYTE SUCH AS LACTATE

Publication No: WO1999/017114
Pub. Date - Int. Class - Applicant: - 08.04.1999 - G01N 33/487 - PEPEX BIOMEDICAL, LLC
The present disclosure relates to an on-line lactate sensor arrangement. The sensor arrangement includes a lactate sensor, a catheter for withdrawing a test sample, and a first fluid flow line providing fluid communication between the lactate sensor and the catheter. The sensor arrangement also includes a source of sensor calibration and anticoagulant solution, and second fluid flow line providing fluid communication between the source of sensor calibration and anticoagulant solution and lactacte sensor.


Title: ASSAYS FOR DIAGNOSIS OF THROMBOPHILIC DISEASE

Publication No: WO1999/002992
Pub. Date - Int. Class - Applicant: - 21.01.1999 - G01N 33/86 - THE MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK
The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The method of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.


Title: DIAGNOSTIC ASSAYS USING SOLUBLE ENDOTHELIAL CELL PROTEIN C/ACTIVATED PROTEIN C RECEPTOR

Publication No: WO1999/000673
Pub. Date - Int. Class - Applicant: - 07.01.1999 - G01N 33/564 - OKLAHOMA MEDICAL RESEARCH FOUNDATION
Plasma EPCR has been isolated, characterized and shown to block cellular protein C activation and APC anticoagulant activity. Plasma EPCR appears to be about 43,000 daltons and circulates at approximately 100 ng/ml (98.4 ± 27.8 ng/ml, n = 22). Plasma EPCR bound activated protein C with an affinity similar to that of recombinant soluble EPCR (Kdżapp? approximately 30 nM), and inhibits both protein C activation on an endothelial cell line and APC anticoagulant activity in a one-stage factor Xa clotting assay. Soluble plasma EPCR appears to attenuate the membrane-bound EPCR augmentation of protein C activation and the anticoagulant function of activated protein C. Soluble EPCR has also been detected in urine. Levels of soluble EPCR can rise ...


Title: USE OF FVIIA FOR THE TREATMENT OF BLEEDINGS IN PATIENTS WITH A NORMAL BLOOD CLOTTING CASCADE AND NORMAL PLATELET FUNCTION

Publication No: WO1998/058661
Pub. Date - Int. Class - Applicant: - 30.12.1998 - A61K 38/48 - NOVO NORDISK A/S
The present invention is generally directed toward the use of Factor VIIa (FVIIa) to achieve haemostasis in certain situations when the haemostatic system including the coagulation cascade and platelets is functioning normally. Thus FVIIa may be used to potentiate, or enhance, the normal haemostatic system in situations where bleeding can be foreseen and where prevention or treatment of such bleeding in needed or desirable. In spite of a normal haemostatic system, extensive bleedings may occur in association with surgery or other types of tissue damage, e.g. severe trauma. FVIIa may also be used when the bleeding is diffuse and poorly respondign to current haemostatic techniques and therapies (e.g. haemorrhagic gastritis and profuse uterine...


Title: HEPARIN-INDEPENDENT, HIGH SENSITIVITY PLATELET FUNCTION EVALUATION TECHNIQUE

Publication No: WO1998/049563
Pub. Date - Int. Class - Applicant: - 05.11.1998 - G01N 33/86 - MEDTRONIC, INC.
An improved apparatus and method for performing activated clotting time tests, including their use for evaluating platelet functionality of a blood sample. The apparatus includes a plurality of test cells. Each of the cells comprises a heparin-inactivating agent, an anticoagulant agent, and a clotting reagent. At least one of the test cells further comprises a platelet activating agent. The clotting time is determined for each of the aliquot portions, and the relative clotting times of the aliquot portions in the cells are determinative of the platelet functionality of the sample. The method comprises the steps of combining a heparin-inactivating agent, an anticoagulant agent, a clotting reagent, a platelet activating agent, and the sample ...


Title: N-SULPHATED HYALURONIC ACID COMPOUNDS, DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION

Publication No: WO1998/045335
Pub. Date - Int. Class - Applicant: - 15.10.1998 - A61L 24/08 - FIDIA ADVANCED BIOPOLYMERS, S.R.L.
The present invention is directed to novel sulphated compounds of hyaluronic acid and derivatives thereof, optionally salified, wherein the glucosamines are partially N-sulphated or partially N-sulphated and partially or totally O-sulphated in position 6. The compounds of the invention have anticoagulant and antithrombotic activities and are useful in the preparation of pharmaceutical compositions and biomaterials and in the production of coatings for biomedical objects.


Title: RECOMBINANT PROTEIN C AND PROTEIN S VARIANTS

Publication No: WO1998/044000
Pub. Date - Int. Class - Applicant: - 08.10.1998 - A61K 38/00 - T.A.C. THROMBOSIS AND COAGULATION AKTIEBOLAG
The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequence to wild-type blood coagulation component capable of expressing anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC), activated protein C (APC) and protein S (PS), said variant component being capable of expressing an anticoagulant activity, which is enhanced in comparison with the anticoagulant activity expressed by the corresponding wild-type blood coagulation component, and said variant component differing from the respective wild-type component, in that it contains in comparison with the said wild-type component at least one amino acid residue modificatio...


Title: MICROPATHOLOGICAL PATIENT REPLICA BASED ON UNADULTERATED WHOLE BLOOD

Publication No: WO1998/041609
Pub. Date - Int. Class - Applicant: - 24.09.1998 - C12M 1/20 - BARNES, Allen, C.
A patient replica is created from a layered culture medium where solid culture medium is formed so that a discontinuity exists between the layers. An infusion port is provided in registration with the discontinuity so that a fresh unadulterated sample of patient blood can be infused into the discontinuity to form a thin layer of blood between the layers of culture medium. The thin layer obviates the requirement for any anticoagulant allowing blood-borne pathogens to be readily cultured without using broth. Further antibiotics or other drug samples may be placed on the surface of the culture medium above the blood layer so that the antibiotic can diffuse through the culture medium and reveal the sensitivities of the cultured pathogens. Other...


Title: RED BLOOD CELL COMPOSITIONS AND METHODS FOR COLLECTING AND STORING RED BLOOD CELLS

Publication No: WO1998/041087
Pub. Date - Int. Class - Applicant: - 24.09.1998 - A01N 1/02 - BAXTER INTERNATIONAL INC.
Methods are disclosed for the collection of red blood cells whereby whole blood is combined with an anticoagulant, red cells are separated from the whole blood and the separated red cells are combined with a storage solution. The red cells may be stored for an extended period of time.


Title: CONTROLLER FOR DELIVERY OF FLUIDS

Publication No: WO1998/030275
Pub. Date - Int. Class - Applicant: - 16.07.1998 - A61M 1/00 - HARVEST TECHNOLOGIES, LLC
A flow-control apparatus uses feedback to control the delivery rate of an anticoagulant to shed blood that is recovered in a blood-salvaging system. An electronic circuit (46) detects the flow rate at which an anticoagulant is added to the collected blood such that the rate of anticoagulant flow is a function of the flow rate of the collected blood. A second timing circuit (42) provides an additional flow of anticoagulant at a rate independent of the flow rate of the collected blood. The flow rate of the anticoagulant is controlled by passing a tube (8) carrying the anticoagulant through a pinch mechanism. The pinch mechanism is electrically controlled by the timing circuit and by the circuit that detects the flow rate of collected blood by...


Title: ANTICOAGULANT COMPOSITION

Publication No: WO1998/029126
Pub. Date - Int. Class - Applicant: - 09.07.1998 - A61K 31/727 - SHERWOOD MEDICAL COMPANY
A blood collection device including a sealed area with a soluvated, non-aqueous anticoagulant composition positioned therein. The preferred anticoagulant composition comprises heparin, polyethylene glycol and optionally, deionized water and one or more salts.


Title: PROCESS OF PREPARATION OF AN AUTOLOGOUS FIBRIN GLUE

Publication No: WO1998/011925
Pub. Date - Int. Class - Applicant: - 26.03.1998 - A61L 24/10 - TARANTINO, Flavio
A process of preparation of autologous fibrin glue for surgical use is disclosed, comprising the steps of taking a sample of blood of the same patient and of concentrating progressively by centrifugation the sample for obtaining a basic product, which when mixed with a starter and other suitable additives produces the fibrin glue ready to be used. A preferred embodiment of the process consists of a closed system using three different plastic bags connected to one another by sealed tubes. More particularly in the first bag the blood sample taken from the patient is collected and mixed with an anticoagulating agent, then separating the plasma from the erythrocytes by centrifugation, said plasma is transferred into the second bag provided with...


Title: SULFATED POLYSACCHARIDES AND USES THEREOF IN MEDICAL TREATMENT

Publication No: WO1998/011141
Pub. Date - Int. Class - Applicant: - 19.03.1998 - A61K 31/715 - JOHNSON &JOHNSON MEDICAL LIMITED
The invention provides sulfated oxidised regenerated cellulose compounds, sulfated alginates, and the salts and hydrates thereof. The compounds are obtained by sulfation of oxidised regenerated cellulose with sulfur trioxide. The invention also provides pharmaceutical compositions comprising the compounds, in particular compositions for the treatment of medical conditions mediated by a matrix metalloproteinase and anticoagulant pharmaceutical compositions.


Title: FACTOR VII-BINDING REAGENT

Publication No: WO1997/049684
Pub. Date - Int. Class - Applicant: - 31.12.1997 - A61K 31/16 - NOVO NORDISK A/S PETERSEN, Lars, Christian OLSEN, Ole, Hvilsted RICHTER, Stefan, Lutz JAKOBSEN, Palle
Compounds of general formula (Ib) wherein X is a chain, aliphatic or comprising hetero atoms as chain members; and R1 is hydrogen, an amino group (optionally substituted with methyl), or a methyl group; and R2 is hydrogen, or a methyl group; or X, in combination with C2, R1, R2, N1, and C3, forms a carbocyclic or heterocyclic system; and wherein the distance between C1 and C3 is from about 0.37 nm to about 0.77, e.g. about 0.57 nm to about 0.67 nm; and pharmaceutically acceptable salts thereof; are zinc chelating agents. The compounds show anticoagulant properties due to an inhibitory interaction with factor VII and serum level Zn2+. The zinc chelating agents bind to factor VIIa and induces replacement of calcium ions with zinc ions in the ...


Title: ELECTROPERATION-MEDIATED INTRAVASCULAR DELIVERY

Publication No: WO1997/049450
Pub. Date - Int. Class - Applicant: - 31.12.1997 - A61N 1/30 - GENETRONICS, INC.
A method for sustained intravascular delivery via electroporation is provided. The method is useful for delivery of therapeutic compositions such as antithrombotic and anticoagulant agents. The invention also provides a catheter apparatus for introducing a composition into at least one cell in a vessel in a subject.


Title: ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES

Publication No: WO1997/046576
Pub. Date - Int. Class - Applicant: - 11.12.1997 - A61K 38/00 - GYOGYSZERKUTATO INTÉZET KFT. BAJUSZ, Sßndor JUHASZ, Attila BARABAS, Éva FEHÉR, Andrßs SZABO, Gabriella SZÉLL, Erzsébet VÉGHELYI, Irén LAVICH, Emilia KASZAS, Éva LANGO, Jľzsef MORAVCSIK, Imre SZEKER, Agnes TASCHLER, Zsuzsanna TOTH, Gßbor MOHAI, Zsuzsanna S
The invention relates to new peptidyl-arginine aldehyde derivatives of general formula (I): Q-D-Xaa-Pro-Arg-H, wherein Q represents an acyl group of formula Q'-O-CO-, where Q' represents an alkyl group with 1-3 carbon atoms, D-Xaa represents 3-cyclobutyl-D-alanyl- or 3-cyclo-pentyl-D-alanyl- group, Pro stands for L-prolyl- group, and Arg stands for L-arginyl- group, and acid-addition salts thereof formed with an organic or inorganic acid and pharmaceutical compositions containing the same. The compounds of formula (I) have valuable therapeutic, particularly anticoagulant, properties together with inhibiting platelet functions and thrombosis development.


Title: ANTICOAGULANT PEPTIDE FRAGMENTS DERIVED FROM APOLIPOPROTEIN B-100

Publication No: WO1997/043311
Pub. Date - Int. Class - Applicant: - 20.11.1997 - A61K 38/00 - ROYAL FREE HOSPITAL SCHOOL OF MEDICINE BRUCKDORFER, Karl, Richard ETTELAIE, Camille
The present invention provides a peptide compound of formula Z1-K-A-Q-X1-K-K-N-K-H-R-H-S-X2-T-Z2 [SEQ ID No. 1] where: X1 represents S or Y, X2 represents T or I, Z1 represents the N terminus of the peptide, or from 1 to 47 amino acids, Z2 represents the C terminus of the peptide, a terminal amide group, or from 1 to 77 amino acids; or a variant of this peptide which contains one or more internal deletions, insertions or substitutions and which substantially retains anti-coagulant properties of apoB-100.


Title: TSETSE THROMBIN INHIBITOR

Publication No: WO1997/043309
Pub. Date - Int. Class - Applicant: - 20.11.1997 - A61K 38/00 - YALE UNIVERSITY CAPPELLO, Michael AKSOY, Serap
A potent and specific inhibitor of the human coagulation protease thrombin was isolated and purified from salivary gland extracts of the tsetse fly, Glossina morsitans morsitans, an important vector of African trypanosomiasis. The inhibitor is a low molecular weight polypeptide exhibiting a molecular weight of 3530 Daltons (as determined by laser desorption mass spectrometry). Amino terminal sequencing of the purified protein reveals no homology to any previously identified serine protease inhibitor or naturally occurring anticoagulant. In addition, it is also a potent inhibitor of thrombin-induced platelet aggregation. The polypeptide is useful in pharmaceutical and vaccine compositions.


Title: METHOD AND KIT FOR SEPARATING PLASMA FROM WHOLE BLOOD

Publication No: WO1997/029369
Pub. Date - Int. Class - Applicant: - 14.08.1997 - G01N 33/49 - MICRO DIAGNOSTIC INNOVATIONS NEDERLAND B.V. DE ROOIJ, Felix, Wilhelmus, Marie
The invention relates to a method for separating plasma from whole blood, in which: a) a mixture of whole blood, a blood anticoagulant and a diluent is prepared in a container provided with a sealing cap, and b) the mixture obtained under a) is passed through a filter containing glass fibres. Preferably, step a) is carried out in a hypodermic syringe in which a pressure prevails which is lower than the pressure prevailing at ambient temperatures. The invention also relates to a kit for separating plasma from whole blood, the kit comprising at least a container which contains a diluent, and a filter containing glass fibres.


Title: MEASUREMENT OF COMPLEMENT ACTIVATION BY BIOMATERIALS BY MEANS OF COMPLEMENT CONVERTASE CLEAVAGE OF PEPTIDE SUBSTRATES

Publication No: WO1997/028276
Pub. Date - Int. Class - Applicant: - 07.08.1997 - C07K 5/083 - STICHTING ONDERZOEKSBELEID CARDIOPULMONALE CHIRURGIE VAN OEVEREN, Willem DE HAAN, Jacob
A process for determining complement activation due to contact between a biomaterial and a complement system, by incubating in vitro the biomaterial with the complement system and determining the formation of a complement convertase by using a substrate of the complement convertase and detecting substrate cleavage. The biomaterial after said incubation with the complement system may be separated therefrom and formation of a complement convertase may be determined with the separated biomaterial, the separated complement system, or both. The complement convertase may be Factor B convertase, C3 convertase or C5 convertase, and the substrate may be a labeled oligopeptide comprising an amino acid sequence corresponding to the cleavage site of th...


Title: HYBRID FACTOR VIII WITH MODIFIED ACTIVITY

Publication No: WO1997/018315
Pub. Date - Int. Class - Applicant: - 22.05.1997 - A61K 38/00 - IMMUNO AKTIENGESELLSCHAFT
Hybrid proteins which affect blood coagulation comprise a region from a donor anticoagulant or antithrombotic protein, and the resulting hybrid protein has a modified biological activity. Information concerning the hybrid proteins implicates DNA sequences encoding the proteins and hosts, including transgenic animals, that possess these DNA sequences; antibodies directed against hybrid proteins; methods of modifiying the properties of proteins; and treatment methods employing hybrid proteins.


Title: POLYFLUOROALKYL TRYPTOPHAN TRIPEPTIDE THROMBIN INHIBITORS

Publication No: WO1997/012904
Pub. Date - Int. Class - Applicant: - 10.04.1997 - A61K 38/00 - HOECHST MARION ROUSSEL, INC.
This invention relates to polyfluoroalkyl tryptophan tripeptides and to compositions containing them. The compounds are highly selective thrombin inhibitors which provide anticoagulant effects useful in the treatment of thrombin conditions and in preventing the coagulation of stored whole blood and blood products.


Title: BLOOD PROCESSING SYSTEMS WHICH MONITOR CITRATE RETURN

Publication No: WO1996/040400
Pub. Date - Int. Class - Applicant: - 19.12.1996 - A61M 1/30 - BAXTER INTERNATIONAL INC.
Blood collection systems minimize citrate toxicity in donors. The systems convey whole blood (WB) at a prescribed rate into a separation device (12) for separation into red blood cells (RBC) and a plasma constituent (PRP). The systems add anticoagulant including citrate from container (C1) to the whole blood (WB). The systems control addition of anticoagulant from container (C1) using controller (18).


Title: BLOOD COLLECTION AND SEPARATION SYSTEM

Publication No: WO1996/040319
Pub. Date - Int. Class - Applicant: - 19.12.1996 - A61M 1/00 - TRANSFUSION TECHNOLOGIES CORPORATION
The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a variable-volume rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to seperate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separat...


Title: METHOD AND APPARATUS FOR CONTROLLING CONCENTRATIONS IN VIVO AND IN TUBING SYSTEMS

Publication No: WO1996/039209
Pub. Date - Int. Class - Applicant: - 12.12.1996 - A61M 1/34 - COBE LABORATORIES, INC.
A method and apparatus for maximizing the total amount of blood processed during an apheresis procedure by optimizing the concentration of anticoagulant in a donor/patient and the associated extracorporeal tubing set is provided. A simplified model of an anticoagulant accumulation in a donor/patient's body is used to calculate an optimal anticoagulant infusion rate profile to the donor/patient during a blood processing procedure. A maximum acceptable anticoagulant concentration in the donor/patient acts as an upper limit on the rate at which anticoagulant may be infused to the donor/patient using the optimized infusion rate profile. A minimum acceptable anticoagulant level acts as a lower limit in optimally controlling the anticoagulant con...


Title: STABLE POLYMERIZED HEMOGLOBIN BLOOD-SUBSTITUTE

Publication No: WO1996/029346
Pub. Date - Int. Class - Applicant: - 26.09.1996 - A01N 1/02 - BIOPURE CORPORATION
A method for producing a stable polymerized hemoglobin blood-substitute from blood characterized in the use of a chromatographic column, is disclosed. The method of this invention includes mixing blood with an anticoagulant to form a blood solution, washing the red blood cells in the blood solution and then separating the washed red blood cells from the white blood cells. This method also includes disrupting the red blood cells to release hemoglobin and form a hemoglobin solution, which is then treated by high performance liquid chromatography to form a hemoglobin eluate. The hemoglobin eluate is then deoxygenated, contacted with a first reducing agent to form an oxidation-stabilized deoxygenated hemoglobin solution, and mixed with a cross-...


Title: PLATELET GLUE WOUND SEALANT

Publication No: WO1996/027397
Pub. Date - Int. Class - Applicant: - 12.09.1996 - A61K 35/14 - QUANTIC BIOMEDICAL PARTNERS
A plasma-buffy coat concentrate that comprises plasma, platelets at a concentration of at least 1.0 x 109 cells/ml, and fibrinogen at concentration of at least 5 mg/ml is described. The plasma-buffy coat concentrate can be combined with a fibrinogen activator to form a platelet glue wound sealant. A method for processing blood to produce the plasma-buffy coat concentrate is also provided. The method comprises centrifuging anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture. Water is removed from the mixture to produce the plasma-buffy coat concentrate. A fibrinogen activator is mixed with the plasma-buffy coat concentrate to produce a wound sealant, which can then be applied to a wound to facilitate sealin...


Title: CONTROLLING DONOR BLOOD CHARACTERISTICS

Publication No: WO1996/018292
Pub. Date - Int. Class - Applicant: - 20.06.1996 - A61K 35/14 - BAXTER INTERNATIONAL INC.
A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ration greater than about 30 %. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on st...


Title: NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS

Publication No: WO1996/012021
Pub. Date - Int. Class - Applicant: - 25.04.1996 - A61K 38/00 - CORVAS INTERNATIONAL, INC. VLASUK, George, Phillip STANSSENS, Patrick, Eric, Hugo MESSENS, Joris, Hilda, Lieven LAUWEREYS, Marc, Josef LAROCHE, Yves, Rene JESPERS, Laurent, Stephane GANSEMANS, Yannick, Georges, Jozef MOYLE, Matthew BERGUM, Peter, W.
Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.


Title: PROCESS FOR PREVENTING ACTIVATION OF ENZYME SYSTEMS IN HAEMODIALYSIS AND IN SIMILAR PROCEDURES WITH EXTRACORPOREAL BLOOD CIRCULATION

Publication No: WO1996/002288
Pub. Date - Int. Class - Applicant: - 01.02.1996 - A61M 1/36 - BUTUROVIC PONIKVAR, Jadranka
Process for preventing activation of enzyme systems such as coagulation and activation of complement system or bradykinin system in extracorporeal blood circulation in haemodialysis and similar procedures, by means of sequential anticoagulation, wherein in the first 15 to 30 minutes of haemodialysis or of procedure which is similar to haemodialysis, sodium citrate or nafamostat mesylate, preferably sodium citrate, is given into a dialysis line as anticoagulant, then adding of a heparin-free anticoagulant is stopped and there is started with the addition of heparin in the conventional total dose, this addition being carried out till the end of dialysis, is disclosed. By the process according to the invention a universal routine haemodialysis...


Title: SCHISTOSOMA PROTEIN AND USES THEREOF

Publication No: WO1995/035370
Pub. Date - Int. Class - Applicant: - 28.12.1995 - A61K 38/00 - IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY &MEDICINE AGNEW, Alison GUTSMANN, Volker
The use of a protein obtainable from a Schistosoma as a pharmaceutical is described. In particular, the protein can be used as a blood anti-coagulant or as a vaccine. In particular, the protein is antigen HB14 obtainable from a Schistosoma, preferably S. haematobium.


Title: TRANSMUCOSAL DELIVERY SYSTEM

Publication No: WO1995/034286
Pub. Date - Int. Class - Applicant: - 21.12.1995 - A61K 9/00 - MINNESOTA MINING AND MANUFACTURING COMPANY
A device for delivering a heparinic anticoagulant across a mucosal surface in order to achieve or maintain a therapeutically effective blood level of the heparinic anticoagulant. The device involves a matrix containing a therapeutically effective amount of a heparinic anticoagulant, and a mucoadhesive or other mechanism for maintaining the matrix in contact with the mucosal surface for a time sufficient to allow release of the heparinic anticoagulant to the mucosal surface.


Title: METHOD AND MEANS FOR DETECTING AND TREATING DISORDERS IN THE BLOOD COAGULATION CASCADE

Publication No: WO1995/029259
Pub. Date - Int. Class - Applicant: - 02.11.1995 - A61K 38/00 - STICHTING CENTRAAL LABORATORIUM VAN DE BLOEDTRANSFUSIEDIENST VAN HET NEDERLANDSE RODE KRUIS VOORBERG, Johannes, Jacobus VAN MOURIK, Jan, Aart MERTENS, Koenraad
This invention relates to the diagnosis of congenital defects in the anticoagulant protein C system. Methods that are disclosed are based on the detection of mutations at the cleavage sites of coagulation factors that are under control of activated protein C (APC). Diagnostic tests include analysis of the APC-cleavage sites of factor V and factor VIII, by using specific primers to amplify selectively from RNA, cDNA derived from RNA or chromosomal DNA, parts of factor V and factor VIII that contain cleavage sites for APC. Methods that monitor the presence of mutations at the cleavage sites for APC and their utility in the diagnosis of thrombo-embolic disease are disclosed. The invention further discloses methods for correcting the defects de...


Title: PERCUTANEOUS DRUG DOSING CLOSURE SYSTEM

Publication No: WO1995/020916
Pub. Date - Int. Class - Applicant: - 10.08.1995 - A61B 17/00 - KENSEY NASH CORPORATION
A resorbable dispensing device (20, 20') for location in a percutaneous incision or puncture (22, 24) extending to an internally located penetratable organic structure within the body of a living being to provide at least a first biologically active material (72) for uptake by the body. The percutaneous incision or puncture includes an opening (22) in the tissue forming penetratable structure and a communicating tract (24) extending from the opening. The dispensing device can be used as a hemostatic closure and basically comprises anchoring means (32, 32', 32'', 32'''), sealing means (30, 30'), and positioning means (34), e.g., a filament. The anchoring means (32, 32', 32'', 32''') is introduced through the opening (22) onto one side of the...


Title: IMPLANTABLE VASCULAR DEVICE

Publication No: WO1995/019200
Pub. Date - Int. Class - Applicant: - 20.07.1995 - A61F 2/06 - FINCH, Charles, David, Jr. KUIPER, Hendrik, Klaas
An implantable device grafted directly to vascular structures for high volume blood and/or fluid infusion and/or removal for such purpose as hemodialysis, apheresis, exchange transfusion, or large volume fluid infusion. The device is also adaptable to intermittent access to the venous or arterial circulations for purpose of blood sampling or giving medications. The device is comprised of an implantable fluid chamber (25) connected to a cannula (15) which is then grafted directly to the vascular structure (e.g. artery or vein). The vascular end of the cannula (15) employs a valve (17) to prevent reflux of blood and subsequent washout of anticaogulant during periods when the device is not in use. The device is accessed percutaneously through ...


Title: NON-ANTICOAGULANT CHEMICALLY MODIFIED HEPARINOIDS FOR TREATING HYPOVOLEMIC SHOCK AND RELATED SHOCK SYNDROMES

Publication No: WO1995/019176
Pub. Date - Int. Class - Applicant: - 20.07.1995 - C08B 37/00 - GLYCOMED INCORPORATED
A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with heparin is disclosed. Such syndromes include degradation of the microvascular structure, immune and gastrointestinal tract dysfunction, and multiple organ failure. The figure shows changes in mean arterial pressure (MAP) and heart rate (HR) in sham-operated, normal saline-treated, heparin-treated, and 2-0-desulfated non-anticoagulant-heparin-treated rats after the initiation of crystalloid resuscitation.


Title: BLOOD COAGULATION RETARDANTS AND DEVICES

Publication No: WO1995/014788
Pub. Date - Int. Class - Applicant: - 01.06.1995 - C12Q 1/56 - UNIVERSITY OF WASHINGTON
The invention provides methods of using anticoagulants to retard the coagulation of blood, so that properties and functions of blood, plasma, and blood cells may be determined analytically. The methods do not interfere with electrochemichal techniques use to detect divalent cations and permit accurate analysis of many analytes within a single blood sample, which currently require separately anticoagulated blood samples. The serine protease inhibitors used may be combined with each other or blood cell activation, aggregation, and adhesion inhibitors in mixtures that provide anticoagulant activity. The methods permit, for the first time, the possibility of using a single blood sample to perform a full range of blood, plasma, and blood cell an...


Title: ASSAY FOR DETECTION OF SELECTIVE PROTEIN C INHIBITION BY PATIENTS

Publication No: WO1995/008121
Pub. Date - Int. Class - Applicant: - 23.03.1995 - G01N 33/86 - OKLAHOMA MEDICAL RESEARCH FOUNDATION
An assay useful for detecting the propensity of patients for thrombotic disease, especially patients having the lupus anticoagulant or antiphospholipid antibodies, is described. The assay is conducted on patient and control plasma in the presence and absence of exogenous Protein C with a membrane source comprising phosphatidylethanolamine and phosphatidylserine. Patients at risk exhibit test results indicating activated Protein C function is inhibited.


Title: METHOD TO ENHANCE TROMBOMODULIN APC GENERATION USING CATIONIC PROTEINS

Publication No: WO1995/007712
Pub. Date - Int. Class - Applicant: - 23.03.1995 - A61K 38/16 - REGENTS OF THE UNIVERSITY OF MINNESOTA
A method of inhibiting blood coagulation in a patient is provided. This method involves administering to the patient an effective anticoagulant amount of a cationic protein; wherein the cationic protein has an isoelectric point of at least about 7.4, and is capable of enhancing the production of activated protein C by a thrombomodulin-thrombin complex by a factor of at least about two. A particularly preferred cationic protein is purified Platelet Factor 4.


Title: DRACULIN, ITS METHOD OF PREPARATION AND USE

Publication No: WO1995/005836
Pub. Date - Int. Class - Applicant: - 02.03.1995 - C07K 14/81 - RHONE-POULENC RORER PHARMACEUTICALS INC. HEMKER, H., Coenraad APITZ-CASTRO, Rafael BEQUIN, Suzette HOLT, John, C. LYNCH, Kevin
This invention provides a novel protein, "Draculin", having anticoagulant activity for mammalian blood. This protein was isolated from the saliva of vampire bats. This invention further provides methods for purifying Draculin, therapeutic uses thereof, isolated nucleic acid molecules encoding Draculin, and methods of preparing Draculin using recombinant DNA technology.


Title: SYSTEMS AND METHODS FOR COLLECTING BLOOD COMPONENTS

Publication No: WO1995/003112
Pub. Date - Int. Class - Applicant: - 02.02.1995 - A61M 1/30 - BAXTER INTERNATIONAL INC.
Systems and methods for collecting cellular-rich concentrates of blood are disclosed. Blood from donor (78) is mixed with anticoagulant (90) and conveyed to a first separation device (12) for separating an anticoagulated cellular suspension from blood. The anticoagulated cellular suspension is conveyed to a second separation device (14) for removing leukocytes. Leukocyte-depleted cellular suspension is conveyed to a third separation device (16) for concentrating the leukocyte-depleted cellular suspension into a cellular-rich concentrate and a cellular-poor component and a portion of the cellular-poor component is returned to the donor (78). A controller (88) is used to control the process including monitoring the rate at which anticoagulant...


Title: CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa

Publication No: WO1994/022910
Pub. Date - Int. Class - Applicant: - 13.10.1994 - A61K 38/00 - THE DU PONT MERCK PHARMACEUTICAL COMPANY
This invention relates to novel cyclic compounds containing carbocyclic ring systems useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, with or without other therapeutic agents, and to methods of using these compounds, with or without other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. This invention also relates to methods of using the cyclic compounds of the invention in combination with anti-coagulants such as warfarin or heparin, or additional anti-platelet agents such as aspirin, piroxicam or ticlopidine, or thrombin inhibitors such as boropeptides, hirudin or...


Title: APHERESIS SYSTEM INCORPORATING ALTERNATIVE SITE FOR ANTICOAGULANT ADDITION

Publication No: WO1994/019031
Pub. Date - Int. Class - Applicant: - 01.09.1994 - A61M 1/30 - BAXTER INTERNATIONAL INC.
An extracorporeal blood processing method and system (14) wherein blood is extracted from a mammalian subject through a blood withdrawal tube (16) having a blood pump (18), such as a peristaltic pump, positioned thereon. A "distal segment" of the blood withdrawal tube (16) extends from the mammalian subject to the inlet side of withdrawal pump (18). A "proximal segment" of the blood withdrawal tube (16) extends from the outlet side of the blood pump (18) to an extracorporeal blood processing apparatus (14). An anticoagulant feed tube (24) is connected to the "proximal segment" of the blood withdrawal tube (16) such that a flow of anticoagulant solution may be combined with blood exiting the outlet of said blood pump (18) and passing through...


Title: NOVEL ANTICOAGULANT COFACTOR ACTIVITY

Publication No: WO1994/017415
Pub. Date - Int. Class - Applicant: - 04.08.1994 - A61K 38/00 - DAHLBÄCK, Björn
A novel blood anticoagulant activity named APC-cofactor 2 activity that is the second cofactor activity to activated Protein C ( = APC) is described. The cofactor activity is likely to be associated with Factor V because it behaves as a protein that can be enriched from plasma with methods that are similar to such methods for Factor V. On SDS-PAGE the enriched fraction gives rise to three molecular bands at 175-250 kd and 100-180 kd and 330 kd, respectively. Different aspects are described, such as preparations enriched or deficient in the cofactor activity; antibody preparations specific for the Factor V sites associated with APC-cofactor 2 activity; diagnostic and therapeutic uses in connection with the treatment of disorders related to d...


Title: ANTICOAGULANT COMPOSITION

Publication No: WO1994/017108
Pub. Date - Int. Class - Applicant: - 04.08.1994 - C08B 37/00 - AMERICAN HOME PRODUCTS CORPORATION
A process is disclosed for the production of an anticoagulant composition which allows for the accurate analysis of blood electrolyte concentrations. Also disclosed is the anticoagulant composition produced in accordance with the disclosed method and an apparatus containing said composition useful in the collection and sampling of blood.


Title: BLOOD TRANSPORT APPARATUS

Publication No: WO1994/005416
Pub. Date - Int. Class - Applicant: - 17.03.1994 - B01F 13/08 - VIRGINIA MASON CLINIC
An apparatus for transporting blood samples (10) within a capillary tube (12) using a rigid plate member (18) to protect the capillary tube (12) during transport. A magnet (14) is magnetically coupled with and thereby moves a ferrous metal flea (16) within the capillary tube (12) to promote mixing of the blood sample and an anticoagulant chemical coating on the inside of the capillary tube (12). The magnet (14) is slid along the length of a recessed guide track (20) to assure that the magnet (14) does not come in contact with the capillary tube (12) with sufficient force to break the capillary tube (12). The magnet (14) has a central archway (36) through which the capillary tube (12) extends to increase the magnetic coupling between the mag...


Title: PREPARATION AND METHOD FOR PRODUCTION OF PLATELET CONCENTRATES WITH SIGNIFICANTLY PROLONGED VIABILITY DURING STORAGE

Publication No: WO1993/021935
Pub. Date - Int. Class - Applicant: - 11.11.1993 - A01N 1/02 - STIFTELSEN FÖR MEDICINSK-TEKNISK UTVECKLING JONSSON, Svante
The invention relates to a water-based preparation to be mixed with blood, containing citrate ions which inhibit coagulation, as well as a method applied at collection of blood from a living organism while adding an anticoagulant substance including citrate ions. The new features of the invention are that acetate, being a physiologic energy source, inter alia for platelets, is included in the preparation and is added to the blood during collection in addition to the anticoagulant substance in order to obtain prolonged shelf-life of the platelet concentrate without increased risk for the donor or patient.


Title: NON-THROMBOGENIC VASCULAR PROSTHESIS

Publication No: WO1993/021860
Pub. Date - Int. Class - Applicant: - 11.11.1993 - A61F 2/06 - INTERVASCULAR, INC.
The invention provides vascular prostheses (10) free of any substance that counteracts an anti-coagulant comprising a base material having inner (16) and outer (14) surfaces, wherein the outer surface has a layer of a material capable of reducing the porosity of said prosthesis to blood or body fluid and a coating of compounded heparin (24) bound thereon, and the inner surface (16) has a coating of compounded heparin (24) bound thereon, the compounded heparin (24) comprising heparin and a cationic surfactant. The present invention also provides a method for forming a vascular prosthesis. The vascular prostheses (10) exhibit an initial low porosity thereby obviating the need for pre-clotting the prosthesis. The compounded heparin (24) coatin...


Title: NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF

Publication No: WO1993/018060
Pub. Date - Int. Class - Applicant: - 16.09.1993 - C07D 207/16 - GYÓGYSZERKUTATÓ INTÉZET KFT.
This invention relates to new peptide derivatives of the general formula (I): A-Xaa-Arg-H, wherein A represents a D- or L-isochroman-1-carbonyl, D- or L-isochroman-3-carbonyl group, furthermore an acyl group of the general formula: D- or DL-A'-CH(OH)-CO, wherein A' represents a phenyl, benzyl, 1-naphthyl, 1-naphthylmethyl, 2-naphthyl, 2-naphthylmethyl, 9-fluorenyl, benzhydryl, cyclohexyl, cyclohexylmethyl, 2-pyridyl, 3-pyridyl or 4-pyridyl group, and Xaa represents an L-prolyl or an L-pipecolinic acid residue, and Arg stands for an L-arginine residue, their acid addition salts formed with an organic or inorganic acid and pharmaceutical compositions containing the same. Furthermore the invention relates to a process for preparing them. The c...


Title: MEASUREMENT OF THE THROMBOLYTIC ACTIVITY OF BLOOD

Publication No: WO1993/012423
Pub. Date - Int. Class - Applicant: - 24.06.1993 - G01N 33/49 - GOROG, Diana
An in vitro method of monitoring thrombolysis of an occlusive thrombus formed under conditions which simulate in vivo is described. Thrombus is formed in a capillary tube by causing blood to flow under pressure from a non-anticoagulated supply thereof through the capillary lumen and into a reservoir in such a way that the thrombus forms solely by shear-stress. Formation of the thrombus is detected and the pressure on the tube is reduced, the reduced pressure being maintained for a predetermined period of time during which the thrombus stabilises. The pressure is then applied on the thrombus across anticoagulated blood from the same sample and lysis of the thrombus is detected. Preferably the supply of anticoagulated blood is produced by mix...


Title: A WHOLE BLOOD ACTIVATED PARTIAL THROMBOPLASTIN TIME TEST AND ASSOCIATED APPARATUS

Publication No: WO1993/009439
Pub. Date - Int. Class - Applicant: - 13.05.1993 - G01N 33/86 - INTERNATIONAL TECHNIDYNE CORPORATION
An activated partial thromboplastin time (APTT) test is described which does not require blood which has been anticoagulated with citrate. The test enables the citrate anticoagulant step to be combined with the contact activation step and hence enables one to employ fresh non-anticoagulated blood specimens to directly perform the APTT test.


Title: VALVE DEVICE

Publication No: WO1993/008851
Pub. Date - Int. Class - Applicant: - 13.05.1993 - A61M 1/00 - HAEMOCELL PLC WILSON, Trevor, William ARMSTRONG, David, Edward
A device for fitting to a hand held instrument, such as a catheter, having a body through which a primary fluid, such as blood, is withdrawn or supplied, and an inlet (25) through which a secondary fluid such as an anticoagulant, may be introduced, for mixing with the primary fluid. A flexible hose (34) terminates at the inlet for supplying the secondary fluid to the inlet. A pinch valve is provided for variably squeezing the flexible hose to control the metering of the second fluid. The pinch valve has an actuating member (6) which is located so as to be actuatable by the same hand of the user as that holding and manipulating the instrument.


Title: APC POLYPEPTIDES AND ANTI-PEPTIDE ANTIBODIES, DIAGNOSTIC METHODS AND SYSTEMS FOR INHIBITNG APC, AND THERAPEUTIC METHODS

Publication No: WO1993/000102
Pub. Date - Int. Class - Applicant: - 07.01.1993 - A61K 38/00 - THE SCRIPPS RESEARCH INSTITUTE
The present invention describes APC polypeptides and anti-peptide antibodies capable of inhibiting activated Protein C anticoagulant activity. The polypeptide and antibody are useful in diagnostic methods and systems for measuring APC in vascular fluid samples. In addition, the polypeptide and anti-peptide antibody are useful in therapeutic methods for inhibiting APC in a human patient.


Title: THROMBORESISTANT COATING FOR DEFOAMING APPLICATIONS

Publication No: WO1992/021387
Pub. Date - Int. Class - Applicant: - 10.12.1992 - A61L 33/00 - BAXTER INTERNATIONAL INC.
A composition for coating medical blood contacting surfaces comprises a mixture of an anticoagulant and a defoaming agent. The coating composition is applied by either dipping the device into a solution containing the mixture or by spraying the mixture onto the surface. Alternatively, the surface can be sequentially dip coated and/or sprayed with the individual components. In a preferred embodiment, the anticoagulant is a quaternary ammonium complex of heparin, preferably stearyldimethylbenzyl ammonium heparin, and the antifoaming agent is a mixture of polydimethylsiloxane and silicone dioxide.


Title: MODULATION OF tPA ACTIVITY BY HEPARIN FRAGMENTS

Publication No: WO1992/017506
Pub. Date - Int. Class - Applicant: - 15.10.1992 - A61K 38/49 - GLYCOMED, INC.
Disaccharides or oligosaccharides which include disaccharide subunits containing at least two negatively charged residues and fragment mixtures formed by partial or complete depolymerization of heparin by nitrous acid are capable of enhancing the ability of endogenous or administered tPA to dissolve blood clots. Disaccharide units which include, in particular, at least two sulfate residues, lack anticoagulant activity but are effective in enhancing the fibrin-specific clotting dissolution activity of tPA.


Title: METHOD AND APPARATUS FOR EXTRACTING FLUID AND RELATED METHOD AND APPARATUS FOR PRESERVING BLOOD FLUID

Publication No: WO1992/003180
Pub. Date - Int. Class - Applicant: - 05.03.1992 - A61B 10/00 - CRYO-CELL INTERNATIONAL, INC.
Methods and apparatus for extracting fetal blood from an umbilical cord and/or placenta include centrifugation, the application of pressure via rollers (890) and vacuum suction. In each apparatus, a conical receptacle (630) holds the placenta and an inflatable balloon (650) is provided for squeezing the placenta to force blood into the umbilical cord. In addition, in a method for preserving umbilical cord blood, a severed umbilical cord is provided which has at least one tubular blood vessel closed at opposite ends to maintain fluid in the vessel. An anticoagulant is added to blood fluids in the vessel, and the blood fluid is moved in the vessel to distribute the anticoagulant throughout the blood.


Title: ANTICOAGULANT PEPTIDES

Publication No: WO1992/001710
Pub. Date - Int. Class - Applicant: - 06.02.1992 - A61K 38/00 - MERRELL DOW PHARMACEUTICALS INC. KRSTENANSKY, John, L.
This invention relates to peptide derivatives which are useful anticoagulant agents.


Title: METHOD AND APPARATUS FOR ADMINISTRATION OF ANTICOAGULANT TO RED CELL SUSPENSION OUTPUT OF A BLOOD SEPARATOR

Publication No: WO1991/019561
Pub. Date - Int. Class - Applicant: - 26.12.1991 - A61M 1/30 - BAXTER INTERNATIONAL, INC.
Method and apparatus for machine separation of blood and blood components that utilizes improved administration of anticoagulant to the red cell suspension output. Anticoagulant (20) is added to incoming whole blood (13) in an amount sufficient to prevent clotting of the whole blood in the flow path upstream of the blood component separator (46), but in an amount insufficient to prevent clotting of the red cell suspension created by the separator. Anticoagulant (20) is added to the red cell suspension downstream (50) of the separator (46) in order to prevent clotting. By adding an additional aliquot of anticoagulant to the red cell suspension, the amount of anticoagulant added to whole blood before separation can be reduced or eliminated, r...


Title: AUTOMATED BLOOD COMPONENT SEPARATION PROCEDURE AND APPARATUS PROMOTING DIFFERENT FUNCTIONAL CHARACTERISTICS IN MULTIPLE BLOOD COMPONENTS

Publication No: WO1991/019554
Pub. Date - Int. Class - Applicant: - 26.12.1991 - A61M 1/30 - BAXTER INTERNATIONAL INC.
Method and apparatus are provided for machine separation of blood into blood components, wherein a preselected fluid such as anticoagulant is added to at least two different locations (16, 112) through the fluid flow path of the set (10), in order to promote the different functional characteristics in different blood components. The method results in reduced incidence of citrate reaction in the blood donor and increased platelet yield in platelet rich plasma (60) collected during the procedure.


Title: NEEDLE ASSEMBLY FOR REDUCED COAGULATION

Publication No: WO1991/019522
Pub. Date - Int. Class - Applicant: - 26.12.1991 - A61M 5/158 - BAXTER INTERNATIONAL INC.
A needle assembly (60) is provided for withdrawing and returning blood and blood components to a patient or other donor, especially in a machine-assisted blood component separating operation, whereby the incidence of clotting and the size of clots formed in the needle is greatly minimized. The needle assembly is especially useful in situations where only low levels of anticoagulant are added to the extracorporeal blood, which, but for the improved needle assembly, would exacerbate the problem of clot formation at the needle. The assembly (60) includes attached tubing (66) having an internal diameter adjacent the blunt end (72) of the needle (68) that is equal to, or preferably less than, the internal diameter of the needle.


Title: NONTHROMBOGENIC GLYCOSAMINOGLYCAN COPOLYMERS

Publication No: WO1991/015252
Pub. Date - Int. Class - Applicant: - 17.10.1991 - A61L 33/00 - CHEMBIOMED, LTD. MAZID, M., Abdul UNGER, Frank, M.
New biocompatible glycosaminoglycan copolymers which are antithrombotic and antithrombogenic, are provided for demanding biomedical applications requiring long-term or permanent maintenance of anticoagulant properties. The novel copolymers of the present invention are comprised of small fragments or segments of glycosaminoglycans such as heparin, copolymerized with synthetic monomeric components. The invention takes advantage of the fact that small segments of heparin, or other glycosaminoglycans, possess and retain antithrombotic activity that retards or prevents the thrombosis. The anticoagulant fragments are conveniently produced by enzymatic or chemical means and copolymerized with synthetic monomers.


Title: PROTEASE NEXIN I/DEXTRAN SULFATE ANTICOAGULANT

Publication No: WO1991/005566
Pub. Date - Int. Class - Applicant: - 02.05.1991 - A61K 38/55 - INVITRON CORPORATION
Compositions and methods to prevent blood clotting by taking advantage of the ability of dextran sulfate to activate protease nexin I (PN-I) are disclosed. PN-I and dextran sulfate are utilized in combination and administered simultaneously or in tandem.


Title: TREATMENT OF ANIMAL BLOOD

Publication No: WO1991/004672
Pub. Date - Int. Class - Applicant: - 18.04.1991 - A23J 1/06 - KALINOWSKI, Andrew
A process for the utilization of blood to produce whole blood or plasma based product for human and animal consumption and for pharmacological use. The improvement resides in the substantial reduction of coagulate retraction so that the liquid and nutrients of the plasma are retained. The process comprises: (i) one or more anticoagulants (for example a chelating or Ca binding agent) are added, while drawing off the blood or blood fraction to prevent premature clotting. The blood is cooled to 18-36 °C; (ii) a coagulant is added suitable for the anticoagulant used, for example NaCl solution; (iii) the addition of an alkali metal halide at or before coagulation substantially reduces blood retraction. Optionally the pH may be reduced to 6.5 - ...


Title: PROCEDURE FOR STORING RED CELLS WITH PROLONGED MAINTENANCE OF CELLULAR CONCENTRATIONS OF ATP AND 2,3 DPG

Publication No: WO1991/004659
Pub. Date - Int. Class - Applicant: - 18.04.1991 - A01N 1/02 - AMERICAN RED CROSS
This invention provides an improved method for prolonging the shelf life of transfusible red blood cells by decreasing the effective osmolality of the suspending solution and increasing the intracellular pH of the cells prior to storage thereof. This invention also provides methods whereby the intracellular pH may be increased. These methods include collecting the cells in an anticoagulant at pH 7.0 or higher and/or washing, diluting or resuspending the cells prior to storage thereof in a biologically compatible buffered solution that contains at least one non-penetrating or substantially non-penetrating anion or non-electrolyte and is substantially free of chloride ions.


Title: FACTOR Xa BASED ANTICOAGULANT COMPOSITIONS

Publication No: WO1990/015619
Pub. Date - Int. Class - Applicant: - 27.12.1990 - A61K 38/48 - OKLAHOMA MEDICAL RESEARCH FOUNDATION
An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a preferred embodiment, Factor Xa, a serine esterase that forms a complex with Factor Va, Ca++, and phospholipid to catalyze prothrombin activation, is first inactivated with an active site inhibitor, such as dansyl-glu-gly-arg-chloromethyl ketone, to form inactivated factor Xa. In another embodiment, Factor Xa is expressed from a gene sequence wherein the portion encoding the active serine region is modified. The inactivated protein retains the ability to bind to endogenous factor Va in vivo, and has a half-life of approximately ten hours. Administratio...


Title: GLUCOSE FREE PRIMARY ANTICOAGULANT FOR BLOOD

Publication No: WO1990/015612
Pub. Date - Int. Class - Applicant: - 27.12.1990 - A61K 35/14 - THOMAS JEFFERSON UNIVERSITY
The present invention provides a novel primary citrate anticoagulant which is essentially free of glucose and its use to optimize the viability of stored platelets. The present invention allows platelets to be stored in plasma or synthetic media without the addition of buffer. Specifically the anticoagulant consists essentially of sodium citrate and citric acid.


Title: CAPILLARY FLOW DEVICE AND METHOD

Publication No: WO1990/013034
Pub. Date - Int. Class - Applicant: - 01.11.1990 - G01N 33/49 - BIOTRACK, INC.
Methods and devices are provided for carrying out activated partial thromboplastin time (APTT) analysis on a whole blood sample to which no anticoagulant has been added by applying the sample to a capillary track (50) contained in a housing (10), wherein the capillary track (50) comprises sample entry and venting ports (20, 60), at least one capillary track (50) connecting the entry and venting ports (20, 60), and reagents (45) capable of initiating an APTT analysis, wherein clotting time is measured by the cessation of blood flow in the capillary track.


Title: METHODS AND COMPOSITIONS FOR INHIBITING PLATELET AGGREGATION

Publication No: WO1990/006128
Pub. Date - Int. Class - Applicant: - 14.06.1990 - A61K 38/00 - BIOGEN, INC. TRUSTEES OF BOSTON UNIVERSITY
This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention and advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods,...


Title: HIRUDIN PEPTIDES

Publication No: WO1990/003391
Pub. Date - Int. Class - Applicant: - 05.04.1990 - A61K 38/00 - BIOGEN, INC.
This invention relates to novel, biologically active peptides which display the anticoagulant activity of hirudin. More specifically, it relates to peptides which are homologous to at least a portion of the carboxy terminal 26 amino acids of hirudin. Such peptides may also be characterized by a modified tyrosine residue. This invention further relates to covalent and peptidomimetic analogs of these peptides which display anticoagulant activity. This invention also relates to compositions, combinations and methods using such peptides or analogs for therapeutic, prophylactic or diagnostic purposes. And this invention relates to novel methods for sulfating tyrosine residues contained within the peptide or polypeptide.


Title: APPARATUS AND METHOD FOR THE AUTOTRANSFUSION OF BLOOD

Publication No: WO1990/000069
Pub. Date - Int. Class - Applicant: - 11.01.1990 - A61M 1/02 - BIODYNAMICS, INC.
Autotransfusion apparatus and methods are disclosed for collecting, processing and returning blood to a patient during or after surgery. The processing step of the autotransfusion system comprises sequential rough filtering and filtering of the blood. Filtering is achieved within a single filter housing which includes a first ultrafiltration zone (30) where blood fluids and anticoagulant are separated and removed from red blood cells, a washing zone (71) where washing solution is injected into the remaining concentrated red blood cell solution and a second filtration zone (32) where washing solution, residual blood fluids and anticoagulant are separated and removed from the washed and concentrated red blood cell solution. The filtration inc...


Title: PROCEDURE AND CONTAINER FOR THE PREPARATION AND STORAGE OF PLATELET CONCENTRATES

Publication No: WO1990/000059
Pub. Date - Int. Class - Applicant: - 11.01.1990 - A61K 35/14 - SIRCHIA, Girolamo REBULLA, Paolo
A procedure for the routine preparation in closed system and storage in a medium made of natural colloid (plasma) and crystalloid solution of PC deprived of leukocytes, which is based on a quadruple blood bag (PB) containing CPD anticoagulant, an empty satellite bag (S1), a satellite bag (S2) containing a synthetic crystalloid solution, a satellite bag with SAGM (or similar) additive solution for red blood cells (RBC), consisting in collecting the blood in the primary bag (PB), in centrifuging the blood bag at high speed, in expressing the supernatant plasma into bag (S1), in collecting 15-20 mL of the buffy-coat (BC) into bag (S2), in adding the SAGM solution of bag (S3) into bag (PB) containing the RBC concentrate, in disconnecting bags (...


Title: SINGLE NEEDLE CONTINUOUS HEMAPHERESIS APPARATUS AND METHODS

Publication No: WO1989/004690
Pub. Date - Int. Class - Applicant: - 01.06.1989 - A61M 1/30 - BAXTER INTERNATIONAL INC.
Blood separation is accomplished by alternately extracting blood from and reinfusing blood into a donor by way of a single needle while simultaneously and continuously separating the extracted blood into constituents. A harness set applicable to a hemapheresis instrument includes a dual-compartment reservoir. A first compartment stores blood during extraction for supply to the separator during reinfusion. The second compartment stores packed cells during collection for return to the donor during reinfusion. The collection and reinfusion cycles are alternated rapidly to preclude clotting in the un-anticoagulated portion of the harness tubing between the venepuncture needle and the Y-connection with the anticoagulant line.


Title: CONTROLLED ADMINISTRATION OF BENEFICIAL AGENT TO BLOOD

Publication No: WO1989/004654
Pub. Date - Int. Class - Applicant: - 01.06.1989 - A61M 1/36 - BAXTER INTERNATIONAL INC.
As one administers blood through a conduit (10) into a container (12), the blood is passed in the conduit across the supply of beneficial agent (18), such as anticoagulant, to cause a controlled amount of beneficial agent to enter the passing blood in a manner that is substantially uniform overtime. The beneficial agent (18) is typically in dry form until it enters into contact with the blood. Accordingly, no substantial portion of the blood is exposed to a significantly higher concentration of the beneficial agent than other portions of the blood.


Title: MULTIPLE BAG SYSTEM

Publication No: WO1989/004639
Pub. Date - Int. Class - Applicant: - 01.06.1989 - A61M 1/02 - BAXTER INTERNATIONAL INC.
A multiple bag system (10) for preparation of blood components. Donated blood tubing (12) communicates at one end with a first blood bag (14). A first compartment (18) is in flow communication with the donated blood tubing (12) the first compartment (18) containing a physiologically-acceptable, dry anticoagulant (20) for blood. Thus, blood may flow through the first compartment (18) to receive a predetermined amount of the anticoagulant (20) and pass through the donated blood tubing (12) to the first blood bag (14). Second blood tubing (30) communicates between the first blood bag (14) and a second blood bag (32). First branch tubing (34) communicates between the first bag (14) and a second compartment (38). The second compartment (38) cont...


Title: METHOD FOR WETTING PLASMAPHERESIS FILTER WITH ANTICOAGULANT

Publication No: WO1989/003229
Pub. Date - Int. Class - Applicant: - 20.04.1989 - A61M 1/36 - BAXTER INTERNATIONAL INC.
A method of wetting a plasmapheresis filter (26) with anticoagulant in a plasmapheresis system having a venepuncture needle (10), a plasma separation device (26) connected in series by a fluid conduit (12), including operating the system such that an initial limited volume charge of anticoagulant is introduced into the conduit (12) for wetting the filter (26) of the separation device in advance of whole blood flowing from the donor towards the separation device (26) and pushing the anticoagulant charge ahead of the whole blood into the separation device (26).


Title: PYRIDOXAL-5'-PHOSPHATE AS AN IN VITRO ANTICOAGULANT

Publication No: WO1988/009177
Pub. Date - Int. Class - Applicant: - 01.12.1988 - A61K 35/14 - KORNECKI, Elizabeth, H.
The use of pyridoxal-5'-phosphate as an in vitro anticoagulant agent which retains the platelet activity of stored whole blood or stored plasma for more than about six hours is disclosed.


Title: CALIBRATING PLURAL PUMP FLUID FLOW SYSTEM

Publication No: WO1988/006466
Pub. Date - Int. Class - Applicant: - 07.09.1988 - A61M 1/36 - HEMASCIENCE LABORATORIES, INC.
A blood constituent processing system (10) uses a disposable plastic fluid flow path (12) into which an anticoagulant must be accurately metered with respect to pumped blood flow. In a preliminary calibration phase, a closed fluid flow path (12) is provided between the anticoagulant pump and the blood pump. One of the pumps is then controlled to inject fluid into such closed path while the other pump is controlled to withdraw fluid from that path at what is nominally an equal fluid flow rate. Changes in fluid pressure within the closed fluid flow path (12) are then monitored (20) and the flow rate of at least one of the pumps is changed as necessary to achieve an approximately constant fluid pressure within the closed fluid flow path (12). ...


Title: HUMAN PROTEINS HAVING ANTICOAGULANT AND ANTI-INFLAMMATORY ACTIVITY

Publication No: WO1988/005659
Pub. Date - Int. Class - Applicant: - 11.08.1988 - A61K 38/00 - ZYMOGENETICS, INC. BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON
Proteins having therapeutic potential as both anticoagulants and as anti-inflammatory agents. The present invention also discloses the use of lipocortins in reducing blood coagulation in warm-blooded animals.


Title: NEUTRALIZING ANTICOAGULANT ACTIVITIES OF LOW MOLECULAR WEIGHT HEPARIN

Publication No: WO1988/002400
Pub. Date - Int. Class - Applicant: - 07.04.1988 - A61M 1/36 - MASSACHUSETTS INSTITUTE OF TECHNOLOGY
A system comprising heparinase to degrade polydispersed low molecular weight heparin fractions and fragments (LMHF) both in vitro and in vivo. In vitro data show that both the APTT and anti-FXa activities of LMHF, including Kabi 2165, PK 10169, CY 216 and CY 222, are nearly completely eliminated by heparinase in less than 20 minutes, even when the LMHF are present at a level ten times greater than normally used clinically.


Title: ENDOTOXIN REMOVAL

Publication No: WO1987/007531
Pub. Date - Int. Class - Applicant: - 17.12.1987 - A61M 1/36 - ROYAL POSTGRADUATE MEDICAL SCHOOL
Endotoxin sorbent comprising a sorbent material selected from the group consisting of polymyxin B and salts, immobilised on a solid phase support, the solid phase-polymyxin B sorbent having been treated with an anticoagulant capable of preventing or limiting fibrin deposition, whereby free anticoagulant binding sites are blocked which may be used to remove endotoxin from endotoxin-containing fluids e.g. from blood in the treatment of gram-negative bacterial shock.


Title: VACUUM TUBE FOR TAKING BLOOD SAMPLES, CONTAINING AN ANTICOAGULANT

Publication No: WO1987/001809
Pub. Date - Int. Class - Applicant: - 26.03.1987 - G01N 33/48 - SVENSSON, Jan, Axel HOOGERVORST, Nicolaas, Wouterus, Wilhelmus
Vacuum tube for taking blood samples, containing an anticoagulant and 0.005 - 0.1 ml per ml blood of formaldehyde or calomel diluted with distilled water in the ratio 1:30.


Title: PLASMAPHERESIS SYSTEM AND METHOD

Publication No: WO1986/005999
Pub. Date - Int. Class - Applicant: - 23.10.1986 - A61M 1/26 - HEMASCIENCE LABORATORIES, INC.
A reliable flow rate plasmapheresis system (10) includes a rotating enhanced vortex type of membrane filter (15) coupled to receive a flow of anticoagulated whole blood and separate concentrate and filtrate in response thereto. An anticoagulant pump (32) is coupled to mix controlled amounts of anticoagulant with the input blood flow. Degradation of plasma flow rate during multiple extraction-reinfusion cycles is inhibited by selecting the starting anticoagulant pH value and controlling the anticoagulant flow rate relative to the whole blood to establish a starting pH value in the range of 6.8 to 7.2, with an anticoagulant to blood ratio in the range of 1:6 to 1:25.


Title: A METHOD AND APPARATUS FOR TAKING BLOOD

Publication No: WO1986/000823
Pub. Date - Int. Class - Applicant: - 13.02.1986 - A61M 1/36 - UNGER, Peter WESTBERG, Eric
A method and apparatus for use when taking blood and collecting the blood taken in a container which contains initially the amount of anticoagulant required to prevent coagulation of the blood taken and collected. In order to minimize the amount of blood exposed to overdosing with anticoagulant it is proposed in accordance with the invention that the major part of the anticoagulant present is held separated from the blood collected in the container during an initial stage of a blood taking and collecting procedure, and that this segregated portion of the anticoagulant is supplied, either continuously or intermittently, to the blood collected during the continued course of taking and collecting blood and mixed therewith. An arrangement accor...


Title: A DEVICE FOR TAKING AND DISPENSING BLOOD SAMPLES FOR THE PURPOSE OF DETERMINING BLOOD SEDIMENTATION

Publication No: WO1985/003350
Pub. Date - Int. Class - Applicant: - 01.08.1985 - A61B 5/15 - TRELL, Anders
A device for taking and dispensing blood samples for the purpose of determining blood sedimentation, comprising a sampling tube (6) which is sealed against the ingress of air and liquid by means of a rubber stopper (8) and in which a partial vacuum either prevails or can be created by means of a displaceable plunger (14) arranged in the sampling tube. The sampling tube contains a given quantity of an anti-coagulent (9), and connected to the sampling tube (6), preferably integral therewith, is a pipette tube (7) having an inner diameter and a length conforming to the standards prescribed for the sedimentation reaction. According to one embodiment, the pipette tube (7) is sealed against the ingress of air and liquid and encloses a partial vac...


Title: COMPOSITION AND SAMPLING RECEPTACLE METHOD FOR TREATING BLOOD WITH ANTICOAGULANT

Publication No: WO1985/000662
Pub. Date - Int. Class - Applicant: - 14.02.1985 - A61B 5/15 - RADIOMETER A/S EISENHARDT, Anne, Rosengaard HANSEN, Ole, Munch
In order to counteract coagulation of a blood sample which is collected from an animal or a human body (24) and introduced into a receptacle, such as a syringe chamber (14), an anticoagulant is added to the sample within the receptacle. The anticoagulant may be capable of binding cation species in the blood, which are subsequently to be measured. Such cation species comprise hydrogen ions, ammonium ions, alkaline metal ions such as potassium and sodium ions, and alkaline earth metal ions such as magnesium and calcium ions. In order to compensate for the proportions of selected cation species which are bound by the anticoagulant an additive containing such cation species is added to the blood sample so as to obtain substantially the same con...


Title: PREPACKAGED FLUID PROCESSING MODULE HAVING PUMP AND VALVE ELEMENTS OPERABLE IN RESPONSE TO APPLIED PRESSURES

Publication No: WO1984/002473
Pub. Date - Int. Class - Applicant: - 05.07.1984 - A61M 1/10 - BAXTER TRAVENOL LABORATORIES, INC.
A disposable prepackaged fluid processing module (20) for deriving plasma from whole blood includes an integral housing (22) wherein anticoagulant (ACD), saline and collection containers (43,44, and 30), tubing segments (27,28,31,56,60), a membrane filter element (141), and other components (63) required in the procedure are contained. Fluid communication between the containers, tubing segments and filter element is provided by a fluid circuit formed by a panel (36) of the housing (22), and an overlying fluid-impermeable flexible sheet member (71). The fluid circuit includes pump and valve elements (130-137) which operate in response to pressures applied to the sheet member. Upon installation of the system in a related actuator apparatus (2...


Title: PLASMAPHERESIS ASSEMBLY AND ASSOCIATED FLUID MANIFOLD

Publication No: WO1983/000813
Pub. Date - Int. Class - Applicant: - 17.03.1983 - A61M 1/02 - BAXTER TRAVENOL LABORATORIES, INC.
A plasmapheresis assembly including a fluid manifold (10) which interconnects the phlebotomy needle (58) of the assembly with a pair of blood collection containers (44, 46). The manifold (10) includes a removably insertable plug member (24) which, when inserted blocks fluid flow through the manifold (10) to retain anticoagulant solution (48) in the containers (44, 46) prior to use and which, after removal, affords fluid flow through the manifold (10) and permits the attachment of a recipient set (70) to the manifold (10).


Title: IMPROVED ANTICOAGULANT SUBSTANCE

Publication No: WO1981/003276
Pub. Date - Int. Class - Applicant: - 26.11.1981 - A61K 35/14 - RIKER LAB INC
Partially depolymerized heparin products having particular analyzable reducing end groups, a process for their preparation and their use as anticoagulants and antithrombotics.


Title: BLOOD SAMPLER

Publication No: WO1980/002106
Pub. Date - Int. Class - Applicant: - 16.10.1980 - A61B 5/15 - AMERICAN HOSPITAL SUPPLY CORP
A device particularly suited for collecting and dispensing an arterial blood sample. A needle (1) is connected to a flexible transparent tube (5) that includes an air exit vent (7) with a nonwet filter (8) so air, but not blood, can exit the filter under arterial blood pressure. A clamp (10) on the tube (5) pinches off a segment of blood and longitudinally strips such blood segment from the tube (5). The tube (5) has an oxygen blocking coating (39) which is covered with a dry anticoagulant coating (40).
...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
World Patents Published from 2010
 
Clck to enlarge and view details
WORLD - PCT PATENT DOCUMENTS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED FROM IN 2010
This list includes World Patent Documents published by PCT. The list was retrieved by searching the claims section of all patent applications. Salient search terms included drugs,
medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors, heparin, warfarin
and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve highly relevant documents.